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INTRODUCTION 
BACKGROUND:                        
              Tuberculosis is a major disease causing death every year 1.8 million 
worldwide and represents the leading cause of mortality resulting from a bacterial 
infection. Introduction in the 60
 „
S of first –line drug regimen resulted in the control of 
the disease and TB was perceived as defeated. 
               In 2011, tuberculosis [TB] remained the second cause of death from 
infectious disease worldwide. It mainly affects the poorest countries of Africa and 
Southeast Asia. In 2010, according to the world health organization [WHO], TB 
incidence and prevalence were estimated at 8.8 and 12 million cases respectively 
about 1.1 million among HIV-positive people died from TB. Most importantly, one 
third of the world population is infected with latent infection and10% of those 
infected people will develop active TB in their life. 
                      The directly observed treatment short-course [DOTS], a multiple 
therapy program developed by WHO is one of the most efficient weapons against the 
global TB epidemic. Nevertheless, the treatment success rate struggles to reach the 
target of 85%.  Unfortunately, first –line treatment can fail due to poor compliance 
which leads to the emergence of multidrug resistance [MDR] strains of 
M.tuberculosis. The number of TB drugs in preclinical and clinical development is 
today higher than that during the past 40 year 
(1) 
TB IN INDIA 
 
                   India is the country with the highest burden of TB, with world health 
organization [WHO] statistics for 2014 giving an estimated incidence 2.2 million 
cases of TB for India out of a global incidence of 9 million. The estimated TB 
prevalence figure for 2014 is given as 2.5 million. It is estimated that about 40% of 
the Indian population is infected with TB bacteria, the vast majority of whom have 
latent rather than active TB 
(2) 
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HISTORY OF TUBERCULOSIS:- 
Tuberculosis (TB) is believed to have been present in humans for thousands of 
years. Skeletal remains show that prehistoric humans (4000 BC) had tuberculosis, and 
tubercular decay has been found in the spines of Egyptian mummies (3000-2400 BC). 
During the 17th century, exact pathological and anatomical descriptions of 
tuberculosis began to appear. In 1679, Sylvius wrote his Opera Medica, in which he 
was the first to identify actual tubercles as a consistent and characteristic change in 
the lungs and other areas of consumptive patients. The earliest references to the 
infectious nature of tuberculosis also appeared in 17th century Italian medical 
literature. 
(3) 
Due to the variety of its symptoms, TB was not identified as a unified disease 
until the 1820s, and was not named tuberculosis until 1839 by J.L. Schonlein. 
In 1854, Hermann Brehmer proposed the idea that tuberculosis was indeed a 
curable disease. The introduction of the sanatorium cure provided the first big step 
toward treatment for tuberculosis. Brehmer himself was a TB patient. His doctor 
advised him to move to a healthier climate, so he spent some time in the Himalayas 
and came home cured. This experience moved him to build the first sanatorium, a 
place where patients could get plenty of fresh air and good nutrition. This setup 
became the blueprint for the subsequent development of sanatoriums. 
On 24 March 1882 Robert Koch discovered the staining technique that 
identified Tuberculosis bacillus and thus treatment begin. In 1890 Robert Koch 
discovered Tuberculin a Diagnostic use when injected in to the skin.
 (3, 5) 
In 1895 Roentgen Discovery of x-rays made possible a early diagnosis of 
Pulmonary disease. In 1908-1920 Attenuated strain of Mycobacterium calmette and 
Guerin were in use after that in 1943 Selman Abraham Waksman discovered 
Streptomycin injections dramatically recovers patients with patients.
(6) 
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In 1950 combination of Streptomycin and Para aminosalicyclic acid were used 
and in 1952 a major drug called Ionized replaces Sanatorium as major treatment 
patients can be treated as out-patients. 
CURRENT THERAPIES: 
             Tuberculosis [TB] is caused by mycobacterium tuberculosis that most often 
affect the lungs. Tuberculosis is curable and preventable. In 1882, the German 
physician Robert Koch isolated the bacterium. Tuberculosis is contagious and 
airborne disease. 
             In 1944, streptomycin was to treat tuberculosis [TB].  This amino glycoside 
interferes with protein biosynthesis through an interaction with the small 30s subunit 
of the ribosome. The discovery of Para amino salicylic acid in 1946 was quickly 
followed by the important discovery of Isoniazid [INH], as one of the most active 
anti-TB drugs used today. Inhibition of mycolic acids biosynthesis, one of the 
essential components of the mycobacterium cell wall was determined as the 
mechanism of action. Pyrazinamide [PZA] appeared as a potential Anti-TB drug in 
1952. 
                  The TB treatment in the 1980s was a great success as it allowed to shorten 
the duration of the therapy from 9 to 6 months. Ethambutol [EMB] and Rifampin 
[RIF], the two last derivatives used in the TB first-line treatment, were discovered 
during the 60s. Ethambutol is an ethylenediamine discovered in 1961, which affects 
the cell wall by specifically targeting the polymerization of arabinogalactan and 
lipoarabinomannan. Finally, Rifampin appeared as a drug of choice for TB treatment 
around 1970, by acting on replicating and non-replicating mycobacteria. This 
derivative belongs to the rifampicin family and inhibits bacterial RNA synthesis by 
binding to the b-subunit of the DNA-dependent polymerase. 
                 The current standard regimen [DOTS] for TB recommended by WHO is a 
combination of isoniazide, rifampicin, ethambutol, and pyrazinamide for 6 months 
therapy. To treat MDR-TB, WHO recommended the use of second-line drugs which 
include amino glycosides [Kanamycin, amikacin], Capreomycin, cycloserin, para-
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aminosalicylic acid, Thionamides [Ethionamide, proethionamide] and 
fluoroquinolones [ciprofloxacin, ofloxacin, Levofloxacin].
 (1) 
TYPES OF TUBERCULOSIS 
(9, 10) 
Tuberculosis is a contagious disease; it affects almost all the important organs 
of the body. Clinically, tuberculosis is broadly categorized into three major categories  
1. Primary tuberculosis.  
2. Secondary tuberculosis.  
3. Disseminated tuberculosis  
Primary tuberculosis:  
When tuberculosis affects a person who had never been exposed to the 
bacterium earlier, the condition is called primary tuberculosis. In this form of 
tuberculosis the source of bacterium is external.  
Secondary tuberculosis:  
It is also known as post primary tuberculosis. This type of tuberculosis occurs 
in a person who previously had TB. In primary TB, the bacterium goes into an 
inactive face while in secondary TB the bacterium regain its active mode and causes 
the symptom. Secondary tuberculosis more infectious than primary TB. Secondary 
TB increases the chance of the infections spread to other organs such as kidneys, 
heart, and brain  
Disseminated tuberculosis:  
           Disseminated means that the tuberculosis has infected the entire body system. 
It is a very rare type of disease. It primarily affects the bones of spines, hips, joints 
and knees and even the central nervous system. It infects the CSF, the GIT, the 
adrenal gland, skin of the neck and even the heart. 
 
CELL WALL:- 
(11) 
        The well - developed cell wall contains a considerable amount of a fatty acid, 
mycolic acid, covalent attached to the underlying peptidoglycan-bound 
polysaccharide arabinogalactan, providing an extraordinary lipid barrier. This barrier 
is responsible for many of the medically challenging physiological characteristics of 
tuberculosis. The composition and quality of the cell wall components affect the 
bacteria‟s virulence and growth rate.   
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            The peptidoglycan polymer confers cell wall rigidity and just external to the 
bacterial cell membrane, another contributor to the permeability barrier of 
mycobacteria. The peptidoglycan polymer confers cell wall rigidity and is just 
external to the bacterial cell membrane, another contributor to the permeability 
barrier of mycobacteria.  
            Another important component of the cell wall is  lipoarabinomannan, a 
carbohydrate structural antigen on the outside of the organism that is immunogenic 
and facilitates the survival of mycobacteria within macrophages. The cell wall is 
key to the survival of mycobacteria and a more complete understanding of the 
biosynthetic pathways and gene functions and the development of antibiotics to 
prevent formation of the cell wall are areas of great interest. 
 
Fig No1:-Structure of cell wall 
 
Pathogenesis of tuberculosis
(12)
:  
            In the lungs, M. tuberculosis is taken up by alveolar macrophages, but they 
are unable to digest the bacterium. Its cell wall prevents the fusion of the 
phagosome with a lysosome. Specifically, M. tuberculosis blogs the bridging 
molecule, early endosomal auto antigen 1(EEA1); however, this blockade does not 
prevent fusion of vesicle filled with nutrients. Consequently, the bacteria multiply 
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unchecked within the macrophages. The bacteria also carried the UreC gene, which 
prevents acidification of the phagosome. The bacteria also evade macrophages-
killing by neutralizing reactive nitrogen intermediates.  tuberculosis usually enters 
the alveolar passages of exposed humans in an aerosol droplet, were its first contact 
is thought be with resident macrophages, but it is also possible that bacteria can be 
initially ingested by alveolar epithelial type II pneumocystis this cell type is found 
in greater numbers than macrophages in alveoli, and M. tuberculosis can infect and 
grow in this pneumocystis ex vivo. 
 
Fig No:2 Pathogenesis of M. Tuberculosis 
 
DIAGNOSIS OF TUBERCULOSIS:-  
              The most common diagnostic test for TB is a skin test where a small 
injection of PPD tuberculin, an extract of the TB bacterium, is made just below the 
inside forearm. The injection site should be checked after 2-3 days, and, if a hard, red 
bump has swollen up to a specific size, then it is likely that TB is present. 
Unfortunately, the skin test is not 100 percent accurate and has been known to give 
incorrect positive and negative readings. However, there are other tests that are 
available to diagnose TB. Blood tests, chest X-rays and sputum tests can all be used to 
test for the presence of TB bacteria and may be used alongside a skin test. MDR-TB 
is more difficult to diagnose than regular. TB it is also difficult. 
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Fig No:3 Diagnosis of  Tuberculosis 
 
TREATMENTS FOR TUBERCULOSIS :-
( 8) 
The majority of TB cases can be cured when the right medication is available 
and administered correctly. The precise type and length of antibiotic treatment 
depends on a person's age, overall health, potential resistance to drugs, whether the 
TB is latent or active, and the location of infection (i.e. the lungs, brain, 
kidneys).People with latent TB may need just one kind of TB antibiotics, whereas 
people with active TB (particularly MDR-TB) will often require a prescription of 
multiple drugs. Antibiotics are usually required to be taken for a relatively long time. 
The standard length of time for a course of TB antibiotics is about 6 months TB 
medication can be toxic to the liver, and although side effects are uncommon, when 
they do occur, they can be quite serious. Potential side effects should be reported to a 
doctor and include: 
 Dark urine 
  Fever  
 Jaundice  
 Loss of appetite 
 Nausea and vomiting 
It is important for any course of treatment to be completed fully, even if the TB 
symptoms have gone away. Any bacteria that have survived the treatment could 
become resistant to the medication that has been prescribed and could lead to 
developing MDR-TB in the future. Directly observed therapy (DOT) may be 
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recommended. This involves a healthcare worker administering the TB medication to 
ensure that the course of treatment is completed 
 
PREVENTION OF TUBERCULOSIS:- 
A few general measures can be taken to prevent the spread of active TB. 
Avoiding other people by not going to school or work, or sleeping in the same room 
as someone, will help to minimize the risk of germs from reaching anyone else. 
Wearing a mask, covering the mouth, and ventilating rooms can also limit the spread 
of bacteria. 
 
 
Fig No: 4 Prevention of Disease 
 
TB VACCINATION:- 
In some countries, BCG injections are given to children in order to vaccinate 
them against tuberculosis. It is not recommended for general use in the U.S. because it 
is not effective in adults, and it can adversely influence the results of skin testing 
diagnoses. The most important thing to do is to finish entire courses of medication 
when they are prescribed. MDR-TB bacteria are far deadlier than regular TB bacteria. 
Some cases of MDR-TB require extensive courses of chemotherapy, which can be 
expensive and cause severe adverse drug reactions in Patients.
 (12, 15) 
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CURRENT STATUS OF TUBERCULOSIS:- 
             Despite all the drugs available today, tuberculosis is still a problem in many 
nations. According to World Health Organization (WHO) estimates, each year, 8 
million people worldwide develop active tuberculosis and nearly 2 million die. While 
the overall rate of new tuberculosis cases has continued to decline in the United States 
since national reporting began in 1953, the annual decrease in tuberculosis cases has 
slowed dramatically. TB continues to kill between 2 and 3 million people every year. 
The WHO estimates that 36 million people will die of tuberculosis by 2020 if it is not 
controlled. 
(2) 
EPIDEMIOLOGY:- 
                   Tuberculosis is estimated to affect 1.7 billion individuals worldwide, with 
8 to 10 million new cases and 1.7 million deaths every year. After HIV, tuberculosis 
is the leading infectious cause of death in the world. Infection with HIV makes people 
Susceptible to rapidly progressive tuberculosis over 50 million people are infected 
with both HIV and M.tuberculosis.  From 1985 to 1992, the number of tuberculosis 
cases in the United States increased by20% because of increase in disease among 
people with HIV, among immigrants, and among those in jail or homeless shelters. 
Because of increased public health efforts, the number of cases of tuberculosis has 
declined since 1993. Currently, there are about 16,000 new cases of active 
tuberculosis in the United States annually, and about 45% of these are in immigrants. 
(17, 18) 
 
Fig No: 5 Epidemiology of Tuberculosis 
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MEDICINAL CHEMISTRY
 (22, 23)
 
Medicinal chemistry and pharmaceutical chemistry are disciplines at the 
intersection of chemistry, especially synthetic organic chemistry, and pharmacology 
and various other biological specialties, where they are involved with design, 
chemical synthesis and development for market of pharmaceutical agents, or bio-
active molecules (drugs). 
In the so called pre-scientific period, natural products having a history as folk 
remedies were in use, but little of the drug therapy of today is based on these remedies 
some of natural products currently used either themselves or as derivatives, were 
often used originally for other purpose, such as arrow poisons, part of religious or 
other rituals, or even cosmetics. Examples of such products include opium, 
belladonna, cinchona bark, curare, nutmeg, Calabar bean, foxglove and squill. 
Development of drug therapy could not progress until knowledge of anatomy 
and physiology had reached the status of science. The empiric observation of Harvey 
and Sydenham were of great importance to this development in the seventeenth 
century. The work of magendie [1783-1855], an instructor of anatomy in Paris, 
probably represents the earliest application of the experimental medicine. 
Following the French revolution, the study and classification of disease made 
considerable progress. Ineffective remedies were recognized and discarded. In 
Germany, much of the drug discovery in the nineteenth century resulted from the 
investigation in the chemical industries mainly concerned with dyes. It was not until 
the twentieth century, that the search for new drugs entities or classes took place in 
university laboratories. 
            The concept of the drug-receptor interaction has undergone much modification 
from 1960s to 1990s. The use of computer graphics to portray drug-receptor 
interaction has also been a notable interaction has been a notable development of the 
decade. 
The approaches to practice of Medicinal chemistry has developed from an  
empiric one involving organic synthesis of new compounds, based largely on 
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modification of structure of known activity, to one that is more logical and less 
intuitive is mostly because of advancement in molecular biology, Pharmacology, and  
Enzymology .
(22) 
ENZYME PROFILE:- 
Resistance against currently used Anti tubercular therapeutics increasingly 
undermines efforts to contain the worldwide tuberculosis epidemic. Recently, 
benzothiazinone [BTZ] inhibitors have shown nanomolar potency against both drug-
susceptible and multidrug-resistance strains of the tubercle bacillus. However, their 
proposed mode of action is lacking structural evidence. The crystal structure of the 
BTZ target, FAD-containing oxido-reductase Mycobacterium tuberculosis DPRE1, 
which is essential for viability. 
Different crystal forms of ligand –free Dpre1 reveal considerable levels of 
structural flexibility of two surface loops that seem to govern accessibility of the 
active site. Structure of complexes with the BTZ- derived nitroso derivative CT325 
reveal the mode of inhibitor binding. 
More recently nitro- benzothiazinone [BTZs] have emerged as a promising 
class of inhibitors, effective against both drug-susceptible and MDR/XDR strains of 
Mycobacterium tuberculosis at significantly lower minimum concentrations [MICs] 
than either isoniazid or Rifampicin, in combination with reduced toxicity. 
Biochemical studies showed that rv3790and the neighboring gene rv3791 code 
for proteins that act in concert to catalyze the epimerization of decaprenylphosphoryl  
ribose[DPR] to decaprenylphosphoryl arabinose [DPA] a precursor for Arabian 
synthesis without which a complete mycobacterium cell wall cannot be produced. 
DPA is the sole known donor substrate for a series of membrane-embedded 
Arabinosyl transferees‟, including the Ethambutol targets Embc, EmbA, and Emb. 
Essentiality of DPA supply and lack of alternative synthetic pathways position 
DPRE1, which is highly conserved in mycobacterium, and Dpre2 at a critical 
intersection of cell wall biosynthesis. A motion confirmed by transposon mutagenesis. 
This situation has led DPRE1 as a magic drug target.
 (27) 
                                                                                                
INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 12 
 
GLOBAL IMPORTANCE ABOUT THE TARGET:- 
The global tuberculosis epidemic and emergence of drug resistance call for 
intensive research on new antimycobacterial agents. Recent development is focused 
mainly on heterocyclic molecules. In many cases, introduction of sulphur has 
improved antimicrobial activity; many drugs feature Sulphur heterocyclic. Thiophene 
derivatives and Thiadiazoles including derived ortho -condensed heterocycles have 
been found to have a wide range of biological activities. This review highlights the 
recent progress in the field with a focus on whole-cell antimycobacterial activity of 
the agents as well as targeting of enzymes from Mycobacterium tuberculosis. Some of 
the compounds have exhibited high activity with submicromolar minimum inhibitory 
concentrations including activity against drug-resistant strains and/or IC50 values for 
a range of enzymes as their targets (InhA, dehydroquinase, Pks13, carbonic 
anhydrates, DprE1). Mechanisms of action, toxicity, and structure-activity 
relationships are also discussed. Several compounds have exhibited promising in vitro 
and in vivo activities and safety profiles, thus constituting novel, promising leads. 
 
Fig NO: - 6 Decaprenylphosphoryl beta-D-ribose 2-epimerase enzyme 
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GENERAL ANNOTATION
 (20) 
Gene name:  DPRE1 
RV number:  Rv3790 
Type          :   CDS 
Function : Together dpre1 [Rv3791, catalyzes epimerization of decaprenyl    
phosphoryl ribose  
                      DPR to decaprenyl phosphoryl arabinose [DPA] in Arabians synthesis.  
Product:  Decaprenylphosphoryl-beta-D-ribose 2-epimerase-1 
Molecular mass: 50163.2 
Isoelectric point: 7.769 
Gene length      : 1386 
Protein length   : 461 
Location [Kb]   : 4235.78 
Functional category: Lipid metabolism 
Proteomics:   Identified in the membrane fraction of M.tuberculosis H37RV using 
ID-SDS-PAGE and ULC-MS/MS [See GU et al., 2003]. 
Identified in the membrane fraction of M.tuberculosis H37RV using 
2DLC/MS [see Mawuenyega et al., 2005]. 
Identified by mass spectroscopy in triton X-114 extracts of 
M.tuberculosis H37RV [see Malan et al., 2010]. Identified by mass 
Spectroscopy in the membrane protein fraction and whole cell lysates. 
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DRUG DESIGN:- 
Drug discovery process involves a rapid search for a small molecule often 
called as lead. A lead molecule is chemical compound which possess pharmacological 
or biological activity. Sources of lead compounds can come from natural sources, 
such as plants, animals, or fungi and also from synthetic chemical libraries. 
LEAD OPTIMIZATION: 
Newly invented pharmacologically active moieties may have poor drug-
likeness and may require lead optimization step. This step involves chemical 
modification of a lead in order to improve their potency, selectively towards binding 
site, pharmacokinetic parameters and reduced toxicity.  
RATIONAL DRUG DESIGN:- 
Drug design, often referred to as rational drug design or simply rational 
design, is the inventive process of finding new medications based on the knowledge 
of a biological target The drug is most commonly an organic small molecule that 
activates or inhibits the function of a biomolecule such as a protein, which in turn 
results in a therapeutic benefit to the patient. In the most basic sense, drug design 
involves the design of molecules that are complementary in shape and charge to the 
biomolecular target with which they interact and therefore will bind to it. Drug design 
frequently but not necessarily relies on computer modeling techniques. This type of 
modeling is sometimes referred to as computer-aided drug design. Finally, drug 
design that relies on the knowledge of the three-dimensional structure of the 
biomolecular target is known as structure-based drug design  In addition to small 
molecules, biopharmaceuticals and especially therapeutic antibodies are an 
increasingly important class of drugs and computational methods for improving the 
affinity, selectivity, and stability of these protein-based therapeutics have also been 
developed.  
The phrase "drug design" is to some extent a misnomer. A more accurate term 
is ligand design (i.e., design of a molecule that will bind tightly to its target). 
Although design techniques for prediction of binding affinity are reasonably 
successful, there are many other properties, such as bioavailability, metabolic half-
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life, side effects, etc., that first must be other properties, such as bioavailability, 
metabolic half-life, side effects, etc., that first must be optimized before a ligand can 
become a safe and efficacious drug. These other characteristics are often difficult to 
predict with rational design techniques. Nevertheless, due to high attrition rates, 
especially during clinical phases of drug development, more attention is being focused 
early in the drug design process on selecting candidate drugs whose physicochemical 
properties are predicted to result in fewer complications during development and 
hence more likely to lead to an approved, marketed drug.  Furthermore, in vitro 
experiments complemented with computation methods are increasingly used in early 
drug discovery to select compounds with more favorable ADME (absorption, 
distribution, metabolism, and excretion) and toxicological properties . 
In contrast to traditional methods of drug discovery (known as forward 
pharmacology), which rely on trial-and-error testing of chemical substances on 
cultured cells or animals, and matching the apparent effects to treatments, rational 
drug design (also called reverse pharmacology) begins with a hypothesis that 
modulation of a specific biological target may have therapeutic value. In order for a 
biomolecule to be selected as a drug target, two essential pieces of information are 
required. The first is evidence that modulation of the target will be disease modifying. 
This knowledge may come from, for example, disease linkage studies that show an 
association between mutations in the biological target and certain disease states.  The 
second is that the target is "druggable". This means that it is capable of binding to a 
small molecule activity can be modulated by the small molecule. Once a suitable 
target has been identified, the target is normally cloned and produced and purified. 
The purified protein is then used to establish a screening assay. In addition, the three-
dimensional structure of the target may be determined. 
The search for small molecules that bind to the target is begun by screening 
libraries of potential drug compounds. This may be done by using the screening assay 
(a "wet screen"). In addition, if the structure of the target is available, a virtual screen 
may be performed of candidate drugs. Ideally the candidate drug compounds should 
be "drug-like", that is they should possess properties that are predicted to lead to oral 
bioavailability, adequate chemical and metabolic stability, and minimal toxic effects.  
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Several methods are available to estimate druglikeness such as Lipinski's Rule of Five 
and a range of scoring methods such as lipophilic efficiency.  Several methods for 
predicting drug metabolism have also been proposed in the scientific literature. 
COMPUTER AIDED DRUG DESIGNING:- 
The most fundamental goal in drug design is to predict whether a given 
molecule will bind to a target and if so how strongly. Molecular mechanics or 
molecular dynamics is most often used to estimate the strength of the intermolecular 
interaction between the small molecule and its biological target. These methods are 
also used to predict the conformation of the small molecule and to model 
conformational changes in the target that may occur when the small molecule binds to 
it. Semi-empirical, ab initio quantum chemistry methods, or density functional theory 
are often used to provide optimized parameters for the molecular mechanics 
calculations and also provide an estimate of the electronic properties (electrostatic 
potential, polarizability, etc.) of the drug candidate that will influence binding affinity.  
            Molecular mechanics methods may also be used to provide semi-quantitative 
prediction of the binding affinity. Also, knowledge-based scoring function may be 
used to provide binding affinity estimates. These methods use linear regression, 
machine learning, neural nets or other statistical techniques to derive predictive 
binding affinity equations by fitting experimental affinities to computationally derived 
interaction energies between the small molecule and the target.  
Drug design with the help of computers may be used at any of the following stages of 
drug discovery: 
1. Hit identification using virtual screening (structure- or ligand-based design). 
2.  hit-to-lead optimization of affinity and selectivity (structure-based design, QSAR, 
etc.). 
 3. Lead optimization of other pharmaceutical properties while maintaining affinity. 
In order to overcome the insufficient prediction of binding affinity calculated 
by recent scoring functions, the protein-ligand interaction and compound 3D structure 
information are used for analysis. For structure-based drug design, several post-
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screening analyses focusing on protein-ligand interaction have been developed for 
improving enrichment and effectively mining potential candidates. Consensus scoring 
Selecting candidates by voting of multiple scoring functions May lose the relationship 
between protein-ligand structural information and scoring criterion Cluster analysis  
Represent and cluster candidates according to protein-ligand 3D information Needs 
meaningful representation of protein-ligand interactions. 
Ideally, the computational method will be able to predict affinity before a 
compound is synthesized and hence in theory only one compound needs to be 
synthesized, saving enormous time and cost. The reality is that present computational 
methods are imperfect and provide, at best, only qualitatively accurate estimates of 
affinity. In practice it still takes several iterations of design, synthesis, and testing 
before an optimal drug is discovered. Computational methods have accelerated 
discovery by reducing the number of iterations required and have often provided 
novel structures.
 (30) 
 
                                       Fig NO: 7 DRUG DISCOVERY CYCLE 
TYPES OF DRUG DESIGN:-  
There are two major types of drug design. The first is referred to as ligand-
based drug design and the second, structure-based drug design. 
 
                                                                                                
INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 18 
 
LIGAND BASED DRUG DESIGN:-  
Ligand-based drug design (or indirect drug design) relies on knowledge of 
other molecules that bind to the biological target of interest. These other molecules 
may be used to derive a pharmacophore model that defines the minimum necessary 
structural characteristics a molecule must possess in order to bind to the target. [30] In 
other words, a model of the biological target may be built based on the knowledge of 
what binds to it, and this model in turn may be used to design new molecular entities 
that interact with the target. Alternatively, a quantitative structure-activity relationship 
(QSAR), in which a correlation between calculated properties of molecules and their 
experimentally determined biological activity, may be derived. These QSAR 
relationships in turn may be used to predict the activity of new analog. 
 
 
 
 
 
NO 
 
NN 
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Fig No: 8Ligand based drug design 
 
STRUCTURE BASED DRUG DESIGN:- 
Structure-based drug design (or direct drug design) relies on knowledge of the 
three dimensional structure of the biological target obtained through methods such as 
x-ray crystallography or NMR spectroscopy.  If an experimental structure of a target 
is not available, it may be possible to create a homology model of the target based on 
the experimental structure of a related protein. Using the structure of the biological 
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target, candidate drugs that are predicted to bind with high affinity and selectivity to 
the target may be designed using interactive graphics and the intuition of a medicinal 
chemist. Alternatively various automated computational procedures may be used to 
suggest new drug candidates.  
Drug discovery cycle highlighting both ligand-based (indirect) and structure-
based (direct) drug design strategies. Current methods for structure-based drug design 
can be divided roughly into three main categories.  The first method is identification 
of new ligands for a given receptor by searching large databases of 3D structures of 
small molecules to find those fitting the binding pocket of the receptor using fast 
approximate docking programs. This method is known as virtual screening. A second 
category is de novo design of new ligands. In this method, ligand molecules are built 
up within the constraints of the binding pocket by assembling small pieces in a 
stepwise manner. These pieces can be either individual atoms or molecular fragments. 
The key advantage of such a method is that novel structures, not contained in any 
database, can be suggested. a third method is the optimization of known ligands by 
evaluating proposed analogs within the binding cavity.  
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Fig NO: 9 Structure based drug design 
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Binding site identification:- 
Binding site identification is the first step in structure based design.  If the 
structure of the target or a sufficiently similar homolog is determined in the presence 
of a bound ligand, then the ligand should be observable in the structure in which case 
location of the binding site is trivial. However, there may be unoccupied allosteric 
binding sites that may be of interest. Furthermore, it may be that only apoprotein 
(protein without ligand) structures are available and the reliable identification of 
unoccupied sites that have the potential to bind ligands with high affinity is non-
trivial. In brief, binding site identification usually relies on identification of concave 
surfaces on the protein that can accommodate drug sized molecules that also possess 
appropriate "hot spots" (hydrophobic surfaces, hydrogen bonding sites, etc.) that drive 
ligand binding.  
SCORING FUNCTIONS:- 
Structure-based drug design attempts to use the structure of proteins as a basis 
for designing new ligands by applying the principles of molecular recognition. 
Selective high affinity binding to the target is generally desirable since it leads to 
more efficacious drugs with fewer side effects. Thus, one of the most important 
principles for designing or obtaining potential new ligands is to predict the binding 
affinity of a certain ligand to its target (and known anti targets) and use the predicted 
affinity as a criterion for selection.  
Due to the large number of drug properties that must be simultaneously 
optimized during the design process, multi-objective optimization techniques are 
sometimes employed.  Finally because of the limitations in the current methods for 
prediction of activity, drug design is still very much reliant on serendipity and 
bounded rationality.  
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SCREENING AND DESIGN:- 
The process of finding a new small molecule [ligand] against a chosen target 
for a particular disease usually involves high-throughput screening[HTS]. 
The structure –activity relationship [SAR] is to improve certain features of the 
lead compound 
 Increase activity against the chosen target 
 Reduce activity against unrelated targets 
 Improve the drug likeness or ADME properties of molecule 
This process will require several iterative screening runs, during which, it is 
hoped, that properties the new molecule entities will improve , and allow the favored 
compounds  to go forward to in vitro and in vivo testing for activity in the disease 
model of choice. A range of parameters can be used to assess the quality of a 
compound, or a series of compounds, as proposed in the Lipinskis Rule of Five. Such 
parameters include calculated properties such as clog p to estimate liphophilicity, 
molecular weight, polar surface area and measured properties, such as potency, in-
vitro measurement of enzymatic clearance etc. some descriptors such as ligand 
efficiency[LE] and lipophilic efficiency[LIPE] combine such parameters to assess 
drug likeness. Other methods, such as virtual high through put screening, where 
screening is done using computer-generated models and attempting to‟‟ dock‟‟ virtual 
libraries to a target, are also often used 
DOCKING  
Docking program is used to fit the ligand molecule into the target structure in 
a variety of position, conformations and orientations. Docking mode is known as 
pose. Each pose scored based on its complementarity to the target in terms of shape 
and properties such as electrostatics in order to identify the most favorable energetical 
pose.  
The quality of any docking results depends on the starting structure of both the 
protein and the potential ligand. The protein and ligand structure need to be prepared 
to achieve the best docking results.  
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PROTEIN PREPARATION  
It is now accepted that the old idea of the “key and lock” interaction of a 
ligand and its protein. Receptor is not an accurate description of most biological 
complexes. The ligand-protein interactions resemble more a “hand and glove” 
association, where both parts are flexible and adjust to complement each other 
induced fit. The can modify their shape and mould their complementarity. So, as to 
increase favorable contacts and reduced adverse interactions, maximizing the total 
binding free energy. It has been found that active site regions of enzymes appear to 
present areas of both low and high conformational stability.  
 
RECEPTOR CONFORMATION  
The three dimensional (3-D) structures of both ligand and protein are 
necessary for the application of docking techniques. While the manifold of 
conformational structures of small molecule may be relatively easy to predict, the 
lowest energy conformation obtained may not correspond to that of the bound ligand. 
Many proteins targeted for drug design do not have an experimentally determined 
structure and, therefore, docking studied cannot be performed directly. In some cases, 
computational techniques can be used to predict the 3D structure of a protein provided 
the structure of a closely related protein homolog is known. Homology modeling or 
sequence threading techniques may be used to generate models of protein structure 
which, although not as good as experimentally determined structures, can be used as 
docking targets. 
 
ADME ANALYSIS: 
(24) 
For a drug to be pharmacologically active and exert the action it should 
posses‟ pharmacokinetic properties like absorption, distribution, metabolism and 
excretion. In the field of drug research and development many failures do occur, as 
they do not undergo these properties satisfactorily. This has to be ruled out earlier in 
the process of drug discovery. Many in-vitro studies are more frequently used to 
evaluate ADME properties. Some computational methods [in silico tools] have been 
evolved to investigate the most suitable drug molecules. 
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Prediction of ADME related properties 
(25) 
Absorption: 
To investigate this in silico models uses simple parameters like log D 
[diffusion coefficient] and polar surface area are the descriptors for hydrogen bonding 
capacity and logp (partition coefficient) values should fall under the prescribed values 
as per the rule of five, which determines the absorption. 
Bioavailability: 
Size and shape of the molecules, lipophilicity and flexibility determines the 
bioavailability. 
Metabolism: 
Various in silico approaches are exisiting in evaluating the metabolism namely 
QSAR and 3D QSAR. 
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BASIC NUCLEUS INTRODUCTION HETEROCYCLIC CHEMISTRY:   
Heterocyclic structures always are a part in the field of research and 
development in organic chemistry. Millions of heterocyclic structures are found to 
exist having special properties and biological importance. A series of thiadiazole have 
been synthesized using an appropriate synthetic route and characterized by elemental 
analysis and spectral data. 
There are various types of thiadiazole rings are present: 
  1, 2, 4-Thiadizole 
1, 3, 4-Thiadizole 
  1, 2, 5-Thiadizole 
  1, 2, 3-Thiadizole 
 
THIADIAZOLE NUCLEUS:   
 1, 3, 4-THIDIAZOLE:   
Thiadiazole contains the five-membered di  unsaturated ring structure having 
molecular structure formula C2H2N2S containing two carbon atoms, two hydrogen , 
two nitrogen‟s  and one sulphur. The ending azole designates a five membered ring 
system with two or more heteroatom, one of which is Nitrogen. Thiadiazoles are 
associated with diverse biological activity probably by virtue of –N=C-S- 
1,3,4- Thiadiazole moiety contain a heterocyclic nucleus in which sulfur 
present at position -1, and two nitrogen atom at position-3&position-4. Thiadiazole 
derivatives have a unique place in the field of medicinal chemistry.   
Thiadiazole is a biologically identical to that of Pyrimidine and Ox diazole and 
given the prevalence of pyrimidine in nature, it is not surprising that thiadiazole 
shown significant therapeutic potential properties. The Sulfur atom of thiadiazole 
imparts improved liposolubility and mesoionic in nature. 
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This literature review shows that the thiadiazole nuclei have Various Biological 
activities such as 
 Anti-tubercular, (39) 
 Analgesic, (37) 
 Anticonvulsant, (40) 
 Anti-inflammatory, (37) 
 Antioxidant, (41) 
 Anticancer,(41) 
 Anti-fungal.(38) 
On view of the importance of the Thiadiazole nucleus. It was decided to design 
nucleus Based on the Thiadiazole nucleus. One hundred different molecules with the 
thiadiazole Scaffold were drawn and docked. 
Thiadiazole is a versatile moiety that exhibits a wide variety of biological 
activities. Thiadiazole moiety acts as “hydrogen binding domain” and “two-electron 
donor system”. It also acts as a constrained pharmacophore. Many drugs containing 
thiadiazole nucleus are available in the market such as Acetazolamide, 
Methazolamide, Sulfamethazole,etc. Thiadiazole can act as the bio-isosteric 
replacement of the thiazole moiety. So it acts like third and fourth generation 
cephalosporin, hence can be used in antibiotic preparations.  
Thiadiazole derivatives possess interesting biological activity probably conferred 
to them by the strong aromaticity of this ring system, which leads to great in vivo 
stability and generally, a lack of toxicity for higher vertebrates, including humans. 
When diverse functional groups that interact with biological receptors are attached to 
this ring, compounds possessing outstanding properties are obtained. 
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2.  LITERATURE REVIEW 
The purpose of Literature Review is to: 
 Establish a theoretical frame work for a topic/ subject area 
 Define Key terms and terminology 
 Identify studies, Models, Case studies etc supporting a topic 
 Define/establish an area of Study 
2.1 The review on following Works provided basic information about the target enzyme, 
DPRE1 and its function. 
Sarah M. Bhatt., et al., (2012),
 (27)
 Structural basis of inhibition of Mycobacterium 
tuberculosis Dpre1 by benzothiazinone inhibitors.
 
 
Maria Loreto in candela, et.al, (2013),
 (28)
 reported that Dpre1, a new taxonomic marker in 
mycobacteria.
  
 Manina, et al., (2010),
 (30)
 reported that Decaprenylphosphoryl-β-D-ribose 2′-epimerase 
from Mycobacterium tuberculosis is a magic drug target. 
 
2.2 The following works throws a light upon the various genomic aspects of 
M.tuberculosis and also various targets intended for drug action:- 
Donald R Ronning., et al., (2012), is targeting the mycobacterium envelope for tuberculosis 
drug development.
 (31) 
Sarala Men on, et al., (2012), studied the Drug resistance profiles of Mycobacterium 
tuberculosis isolates to first line anti-tuberculous drugs.
 (32) 
P.Mudassar, et al., (2011), had a Brief review on Multi Drug resistant Mycobacterium 
tuberculosis.
 (33) 
Christian Leichardt., et al., (2010), had a review on new drugs and new regimens for the 
treatment of tuberculosis: review of the drug development pipeline and implications for 
national programmes.
 (34) 
Sarah L. Kinnings., et al., (2010), reviewed the Mycobacterium tuberculosis Drug and its 
Polypharmacological Implications.
 (35) 
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2.3 The review on following works provided ideas about the Thiadiazole Nucleus and its 
Biological Activity. 
Antimicrobial activity:- 
                                     Kumar, et al., (2011), synthesized the heterocyclic azodyes derived 
from thiadiazole and evaluated them for antimicrobial activity. In this study 5-ethyl-1, 3, 4-
thiadiazole-2-amine was synthesized by a single step reaction. A series of heterocyclic 
azodyes were synthesized by coupling 8-hydroxyquinoline, 2, 6-diaminopyridine, N, N-
dimethyl aniline, 2-napthol and resorcinol with diazotized 5-ethyl-1, 3, 4-thiadiazol-2-amine 
in nitrosyl sulphuric acid. The synthesized compounds were also screened for biological 
activity and showed maximum activity. 
(36) 
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Anti inflammatory and analgesic activity:- 
                                                                      Sainy et al., (2009), synthesized a series of 2-
amino-5-sulfanyl-1, 3, 4-thiadiazole derivatives and   several 2-amino-5-sulfanyl-1, 3, 4-
thiadiazoles and concluded that the compounds were associated with lesser degree of anti-
inflammatory activity when compared to indomethacin. Only compound 4-[5-(4-
Fluorophenylsulfanyl) -[1,3,4] thiadiazol-2-ylamino] benzene sulfonamide  showed 65.90% 
inhibition of paw edema after 3 h at 56 mg/kg (body weight) dose and 66.40% protection in 
acetic acid induced inflammation in mice.
(37) 
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Antifungal Activity:- 
                                                     Liu et al., (2011), reported the antibacterial and antifungal 
activity of 1,3,4-thiadiazoles bearing imidazo [2,1-b] thiazole moiety against S. aureus ATCC 
29213, P. aeruginosa ATCC 27853, E. coli ATCC 25922, and T. tonsurans NCPF245 with 
MIC of 64, 32, and 8 μg/ml, respectively Applying QSAR study, it has been observed that 
positions-2 or position-3 of benzene attached with thiadiazole ring where as electron-
donating and bulky group would be favorable for higher antifungal activity. On the basis of 
COMFA findings, and designed a compound which was found to display a good antifungal 
activity (79.38%).
 (38) 
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Anti tubercular activity:-  
                                              Foroumadi et al., (2002), synthesized 2-(5-nitro-2-furyl) and 2-
(1-methyl- 5-nitro-lH- imidazol-2-yl)-1, 3, 4-thiadiazole derivatives and evaluated in vitro 
anti tuberculosis Activity. In this study two series of 2-(5-nitro-2-furyl) and 2-(1-methyl-5-
nitro-lH-imidazol-2-yl)-5-propyl, ally and propargyl) thio-l,3,4-thiadiazoles derivatives and 
2-(5-nitro-2-furyl)- and 2-(1-methyl-5-nitro-lH-imidazol- 2-yl)-5-(nitro benzyl)thio-l,3,4-
thiadiazole derivatives have been synthesized and evaluated against Mycobacterium 
tuberculosis .and exhibited good activity.
(39) 
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Anticonvulsant activity:- 
                                             Sharma et al., (2011), synthesized a new series of 2-amino-5-
sulfanyl-1, 3, 4-thiadiazole derivatives. All compounds were screened for central nervous 
system activity.  Exhibited significant antidepressant, anxiolytic and anticonvulsant activity 
when compared with the Standard drugs.
 (40) 
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Anticancer activity and antioxidant activity:- 
                                                           Dhanya et al.,(2011), synthesized a series of 6-[3-(4-
chlorophenyl)-1-H-pyrazol-4-yl]-3-[(2-naphthyloxy)methyl][1,2,4]-triazolo-[3,4-b][1,3,4]-
thiadiazole. Were evaluated for their in vitro cytotoxic effects against a panel of 60 human 
tumor cell lines. All the screened compounds showed significant in vitrocytotoxic effects 
against a variety of human tumor cell lines including cells derived from solid tumors such as 
colon, non-small cell lung, central nervous system, ovarian, melanoma, prostate and breast 
cancer, and also few cell lines of renal cancer and leukemia. Substitution of a formyl group at 
the 5- and substituted aromatic and antioxidant activity and exhibited good activities.
 (41)
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Antihypertensive activity:-  
                                                     Turner et al., (1998), synthesized a series antihypertensive 
thiadiazole derivative and evaluated antihypertensive activity and indicated higher activity 
when compared with the Standard and other compounds.
 (42) 
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2.4 Of the Several works of Thiadiazole, few of them are enlisted here in support of 
their Thiadiazole Anti tubercular activity 
  
                  Novli M.N et al., (2013), synthesized a series of imidazo [2, 1-b] 1, 3, 4-
thiadiazole derivatives and the synthesized compounds were synthesized compounds were 
evaluated for their invitro anti tubercular activity against M. tuberculosis H37RV strain by 
using Alamar Blue susceptibility test. Among the tested compounds, 2-(1-methylimidazol-2-
yl)-6-(4-nitrophenyl) imidazo [2, 1-b] 1, 3, 4-thiadiazole have shown the highest inhibitory 
activity with MIC of 3.14µg/ml as compared to other compound.
 (47) 
                                                
N N
S S RAr  
                                                                        REVIEW OF LITERATURE 
 
DEPARTMENT OF PHRMACEUTICAL CHEMISTRY, COP, MMC Page 31 
 
Gadad A.K et al., (2004), Evaluated 6-aryl-2-triflouromethylimidazo [2, 1-b] 1, 3, 4-
thiadiazole derivatives against M. tuberculosis against H37RV strain by radiometric 
BACTEC and broth dilution method. It was found that 4-flouro phenyl derivative causes 
maximum inhibition at 6.25µg/ml concentration. All the synthesized compounds were 
reported to be less active than standard drug Isoniazid.
 (44) 
                                       
                               
N
S
N N
OH
 
 
Shiradhkar M et al., (2005), synthesized a series of S-triazolo [3, 4-b] 1, 3, 4-thiadiazoles 
and screened for their antitubercular activity against M. tuberculosis H37RV. The final data 
of the MIC was compared with the standard drug Rifampicin at 0.03µg/ml concentration 
which showed more than 95% inhibition. Among the derivatives, nitro phenyl derivatives 
were shown to possess maximum activity against M. tuberculosis.
 (43) 
                 
                                         
S
N N
R
N
R 
 
Palkar M.B et al., (2012), synthetized a series anti tubercular activity of some 2-substituted-5, 
6-diaryl substituted imidazo [2, 1-b] 1, 3, 4-thiadiazoles against M. tuberculosis H37RV 
strain by Micro plate Alamar Blue Assay (MABA) method using Isoniazid as the standard 
drug.
(45) 
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S
N
N
N
NOH
CH3
N
 
   
Chitra et al.,(2005), synthesized a 3-heteroarylthioquinoline derivatives of 1,3,4-thiadiazole 
and screened there in vitro anti mycobacterial activity against H37Rv using Middle brook 
7H11 agar medium supplemented with OADC by agar-dilution method. They found that the 
anti tubercular activity was considerably affected by various substituent like 2-methyl-1, 3, 4-
thiadiazole, benzothiazole and 2-phenyl-2H-tetrazole on the 3-position of quinoline ring and 
it was further supported by the fact that compounds with no substitution did not show any 
considerable activity. Compounds 78 and 79 with chloro- add bromo-substituted aromatic 
ring found to be more active (MIC = 3.2–3.5 μg/ml) Analogs having methyl and methoxy 
groups at the C8 of quinoline nucleus showed inhibition (MIC) at 5 μg/ml). (46) 
                                     
N
N
S
N
NH2
Cl
R
R
 Where R- cl, Br R1- OH,  
                                       Compound 78 and 79 
2.5 The review on following works provided ideas for synthesis of the desired chemical 
entities:- 
                 Keerthi Kumar et al., (2013), proposed synthesis of azodye incorporated 5-
phenyl 1, 3, 4-thiadiazole-2-amine single step by diazotization of nitrosyl sulphuric acid 
followed by coupling with heterocyclic moiety.
 (48) 
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N
S
N
NH2
                                               
N
S
N
N
N
R
 
 
Tang, zilong et al., (2015), Presented 2-[1, 3, 4-thiadiazolyl amino methyl] phenols by one 
pot reaction of 2-amino -5-Alkyl [aryl] - 1, 3, 4-thiadiazole and salicylaldehyde the title 
compounds had moderate fungicidal activity.
 (49)
    
S
N N
NH2
R
         +      
OOH
R
                        
OHR
N
S
N
N
R
   
Mathew Bijo et, al. concentrated on synthesis of Schiff bases of 5-phenyl substituted 2-
Amino1, 3, 4-thiadiazole as effective anthelmentics. 
(50) 
                       
S
N N
NH2
R
    
Sandeep Miglani, et al., (2012), the rapid Synthesis of Schiff-bases without Solvent under 
microwave irradiation and their antimicrobial activity
 (52) 
NH2
R + 
O
R
 
N
R
R 
                                                                       -H2O 
Solak N et, al.proposed synthesis of anti tuberculosis activity of 2-(aryl/alkyl amino)-5-(4-
aminophenyl)-1, 3, 4-thiadiazoles and their Schiff bases. 
(52) 
                                                                                                          
Nitrosyl sulphuric acid 
Ethanol 
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S
N N
R
N
R
 
K. Brodowska, et al., (2014), Schiff bases- interesting range of applications in various fields 
of Science, and their anti microbial activity.
 (53) 
                                            OH
N
OH
 
     Foroumadi et al., (2006), synthesized 2-(5-nitro-2-furyl) and 2-(1-methyl- 5-nitro-lH- 
imidazol-2-yl)-1, 3, 4-thiadiazole derivatives and evaluated in vitro anti tuberculosis Activity. 
In this study two series of 2-(5-nitro-2-furyl) and 2-(1-methyl-5-nitro-lH-imidazol-2-yl)-5-
propyl, allyl and propargyl) thio-l,3,4-thiadiazoles derivatives and 2-(5-nitro-2-furyl)- and 2-
(1-methyl-5-nitro-lH-imidazol- 2-yl)-5-(nitro benzyl) thio-l,3,4-thiadiazole derivatives have 
been synthesized and evaluated against Mycobacterium tuberculosis 
                                                  
N N
S S RAr  
 
2.6The review on following works revealed the basis of Spectroscopy Study 
Gurdeep R. Chatwal [2005] wrote a book on, Instrumental methods of chemical analysis.
 (54) 
 
 P.S.Kalsi Text book on Spectroscopy of organic compounds.
 (55) 
 
 Y.R.Sharma, Text book on Elemental organic Spectroscopy.
 (56) 
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2.7 The following literatures were surveyed in depth to provide supporting data for the 
drug design study 
Laurie AT, et.al., (2005), Q Site finder on energy based method for the prediction of protein-
ligand binding site Bioinformatics.
 (58) 
http; // www.modelling leads.ac.uk/q site finder/ 
Sanju joy, parvathy S Nair., et.al, (2006), Detailed comparison of Pro-ligdocking efficiency 
of GOLD, a commercial package and Argus lab, a licensable freeware [Insilco biology 6, 
0053[2006].
(60) 
 
2.8 The review on following works revealed the basis of Alamar blue assay for 
evaluating the anti-mycobacterium action. 
David  A. J. Moore.,et al.,(2008),Inter and Intra assay reproducibility of Micro plate Alamar 
blue assay results for Isoniazid, Rifambicin, Ethambutol, Streptomycin, Ciprofloxin, 
Capromycin, drug suscepbility testing Mycobacterium tuberculosis.
(76) 
 
Todd P. Primm., et al [2007], Recent Advances in Methodologies for the Discovery of 
Antimycobacterial Drugs. 
(77) 
Vanitha JD., et al., [2007], Evaluation of Micro plate Alamar blue assay for drug 
susceptibility testing of Mycobacterium avium complex isolates. Diagnostic Microbiology 
and Infectious Disease. 
(75) 
 
Franzblau SG., et al., Rapid lower technology MIC determination with clinical 
Mycobacterium tuberculosis isolates by using the Micro plate Alamar blue assay. Journal of 
Clinical Microbiology.
 (76) 
Sephra N.Ramprasad studied the various applications of Alamar blue as an indicator. 
Alamar blue is an indicator that is used to evaluated metabolic function and cellular health. 
The Alamar blue bioassay is being utilized to access cell viability and cytotoxicity in a 
biological and environmental system and in a number of cell types including bacteria, yeast, 
fungi, and protozoa. 
(79) 
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Jose d Jesus Alba-Romero et al applied the Alamar blue assay to determine the 
susceptibility to anti-tuberculosis pharmaceuticals. The results showed that the MABA test is 
fast and easy to apply. It is very reliable method to determining the drug susceptibility to 
pharmaceuticals. 
(80) 
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                                               3. Aim and Objective 
AIM:- 
              The aim of this project is to design molecules with potential anti-tubercular 
activity that is capable of inhibiting cell wall synthesis by inhibiting 
Decaprenylphosphoryl-beta-D-ribose2-epimerase-1. The designed compounds will be 
synthesized, characterized and evaluated for biological activity and toxicity. 
OBJECTIVE:- 
The compounds are designed and docked against a specific crucial target, 
Decaprenylphosphoryl-beta-D-ribose2epimerase-1.This is involved in the cell wall 
biosynthesis and Lipid metabolism. The synthesized compounds are expected to act 
on the  same. 
                                       PLAN OF WORK 
DESIGN:- 
In-silico design of Decaprenyl phosphoryl – beta - D-ribose 2 epimerase-1 
inhibitors. 
  DRUG LIKENESS:                   
Determination of Drug likeness 
TOXICOLOGICAL PREDICTION:- 
Toxicological prediction will be carried out for synthesized compounds by in-
silico property explorer like OSIRIS. 
SYNTHESIS:- 
Novel anti-tubercular activity containing compounds are synthesized under 
specific conditions, which is effective against specific microbes. 
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CHARACTERIZATION:- 
The synthesized compounds will be identified and characterized by following 
methods 
1. Melting point. 
 
2.  TLC method 
 
3. Infrared Spectroscopy  
 
4. Nuclear Magnetic Resonance  
 
5. Mass spectroscopy  
 
6. Gas Chromatography and Mass Spectroscopy (GC-MS) and if necessary  
 
7. Liquid Chromatography and Mass Spectroscopy (LC-MS)  
 
BIOLOGICAL EVALUATION:- 
The synthesized compounds will be screened for their anti-tubercular activity 
by in-vitro method called MABA. 
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THE PRESENT STUDY CARRIED OUT BASED ON THE FLOW CHART: 
 
IDENTIFICATION OF LEAD COMPOUND 
 
LEAD OPTIMIZATION 
 
DOCKING OF THE MOLECULE TO THE TARGET PROTEIN 
 
TOP G SCORE COMPOUNDS SELECTED 
 
INSILICO DRUG LIKENESS AND TOXICITY RISK ASSESSMENT 
 
SYNTHESIS 
 
JUSTIFICATION OF PURITY –TLC, GC 
 
 
CHARACTERIZATION –SPECTROSCOPY(IR, NMR, GC-MS, LC-MS) 
 
 
INVITRO ANTI TUBERCULAR ACTIVITY 
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LIST OF COMPOUNDS TO BE SYNTHESIZED:- 
SAMPLE 
CODE 
COMPOUNDS IUPAC 
SDK1 
N
S
N N
OH
 
2-{(E)- [(5-phenyl-1,3,4-
thiadiazol-2-yl)imino] 
methyl}phenol 
 
SDK2 
N
S
N N
OH
 
4-{(E)-[(5-phenyl-1,3,4-
thiadiazol-2-
yl)imino]methyl}phenol 
 
SDK3 
N
S
N N
Cl
Cl
 
(E)-1-(2,4-dichlorophenyl)-N-(5-
phenyl-1,3,4-thiadiazol-2-
yl)methanimine 
 
SDK5 
N
S
N N
N
+
O
-
O
 
(E)-1-(3-nitrophenyl)-N-(5-
phenyl-1,3,4-thiadiazol-2-
yl)methanimine 
 
PAA 
O S
N
N
NH2
 
 
5-(phenoxy methyl)-1,3,4-
thiadiazol-2-amine 
 
HA 
NH
O
S
N N
NH2
 
N-[(5-amino-1,3,4-thiadiazol-2-
yl)methyl]benzamide 
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4. MATERIALS AND METHODS 
DRUG DESIGN:- 
A binding interaction between a small molecule ligand and an enzyme protein 
results in activation or inhibition of the enzyme which results in agonism or 
antagonism, 
GLIDE DOCKING  
Glide is one of the docking programs which predict the binding mode of 
ligand to a protein (target). It ranks the ligands via high-throughput virtual screening. 
Extra prediction mode (XP) was used to rank order the compounds based on the 
interaction with the receptors.  
 Protein preparation 
 Ligand preparation  
 Receptor grid generation 
 Ligand docking (screening)  
 
MOLECULAR DOCKING BY ARGUS LAB SOFTWARE :  
          Docking of ligands is carried out by Argus lab docking software. Docking 
allows the medicinal chemist to virtually screen a set of compounds and predict the 
strongest binding capacity based on various scoring function. It explores ways in 
which two molecules such as ligand and receptor (protein) fit together and docks to 
each other well. The molecule binding to a receptor inhibits its function and thus acts 
as drug.  
Argus lab 4.0 distributed freely for windows platforms by planaria software, is an 
introductory molecular modeling package with academics. Argus docking engine implementry 
in Argus lab approximates an exhaustive search method which is similar to DOCK and 
GLIDE. Flexible ligand docking is possible with Argus lab, where the ligand is described as 
torsion tree and grids are constructed that overlay the binding site. The accuracy of the Argus 
lab docking algorithm takes into account, the key features such as the nature of the binding 
site and the number of rotatable bonds to the ligand.  
Molegro molecular viewer: Molegro molecular viewer is an application which helps in 
analyzing the energies and interaction of the binding site.  
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Q-site finder is an energy-based method for protein-ligand binding site prediction. During 
prediction we use the crystal structures of macromolecules (receptor) with small substrates 
(PDB ID)  
           Identifying the location of binding sites on a protein is of fundamental 
importance for a range of applications including molecular docking. It uses the 
interaction energy between the protein and a simple vanderwaals probe to locate 
energetically favorable binding sites.  
 
4.1 DOCKING PROCEDURE:-[ARUGS LAB SOFTWARE 4.0] 
A.PREPARATION OF PROTEIN: 
STEP1: 
I) Enter Protein PDB ID (4P8Y) In the Protein data bank. 
ii)  Go to download files and Select PDB as text file. 
iii)  Save the downloaded PDB text file to desktop. 
STEP2: 
i) Open Argus lab file                  Open                    Import pdb file from the desktop. 
ii) 3D Structure of the Protein will appear in the workspace of Arguslab. 
iii) Left Side of the Screen Shows molecular tree view. 
iv) Open pdb                  Open Residues                     Open Misc. 
v )From Misc delete the inhibitor and hetero residues, do not delete cofactor 
vi) Open water press shift, select all water molecules and delete. 
vii) Add hydrogen atoms. 
viii) Go the calculation on toolbar           energy by UFF method                   Start. 
Save the prepared protein as   ® agl file format in the desktop. 
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B. IDENTIFICATION / SELECTION OF ACTIVE SITE:- 
 
STEP1:- 
Q-Site finder was opened through online. 
The Pdb format of the protein was imported. 
Found all the active site and make a list out of the common amino acid residues. 
STEP2:- 
Residues                     Open amino acids was Opened. 
Controls were selected and select the amino acids which were listed from the Q-Site 
finder. 
Make sure that all the amino acid residues listed are selected. 
Right Click on the mouse                     make a group from the selected residues                    
give name                Binding site                       OK. 
 
C.PREPARATION OF LIGANDS:- 
Drawn the Structure from Chem. Sketch and Save as MDL mol format. 
The ligands were imported into workspace of Argus lab. 
Clean geometry                    Clean Hybridization.  Select the ligand;   right Click on 
the mouse                    make a group from the residues                            give name                            
ligand           OK. 
The ligand was selected; right click on the mouse                         make a group from 
the residues                     give name                       ligand                            OK. 
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D. DOCKING PARAMETER: 
Calculation was selected from the toolbar                           Dock a ligand. 
Argus Dock as the Docking engine. 
Dock was selected as Calculation type. 
Flexible for the ligand. 
Ascore as the Scoring function. 
Calculation Size. 
Docking was started. 
Save the Docked protein Ligand Complex as Brookhaven PDB files. 
 
E. VISUALIZATION/ INTERPRETATION OF DOCKING: 
Molegro molecular Viewer will help in analyzing the energies and interaction of the 
binding.
(60) 
4.2 LIPINSKIS RULE:- 
(64,65,66) 
 
          Lipinski’s rule of five is a rule of thumb to evaluate drug likeness, ie., or to 
determine if a chemical compound with a certain pharmacological or biological 
activity has the properties that would make it a likely orally active drug in humans. 
The rule was formulated by Christopher A. Lipinski in 1997, based on the observation 
that most medication drugs are relatively small and lipophilic molecules. 
The rule describes molecular properties important for a drug’s pharmacokinetics in 
the human body, including their absorption, distribution, metabolism and excretion 
(ADME). However, the rule does not predict if a compound is pharmacologically 
active.  
 
The rule is important for the drug development where a pharmacologically active 
lead structure is optimized step-wise for increased activity and selectivity, as well as 
drug-like properties as described by Lipinski’s rule. The modification of the 
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molecular structure often leads to drugs with higher molecular weight, more rings, 
more rotatable bonds, and a higher lipophilicity.  
 
Lipinski’s rule says that, an orally active drug has no more than one violation of 
the following criteria:  
 Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or 
more hydrogen atoms) 
 Not more than 15 rotatable bonds. 
 Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms)  
 Molecular weight under 500 Daltons  
 Partition coefficient of log P less than 5. 
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 MATERIALS AND METHODS 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 46 
 
 
4.3 HETEROCYCLIC CHEMISTRY              
Heterocyclic structures always are a part in the field of research and development in 
organic chemistry. Millions of heterocyclic structures are found to exist having 
special properties and biological importance. Among various compounds, I have 
chosen Thiadiazole a five membered ring containing sulfur at position 1 and Nitrogen 
at position 3 and 4. 
                                 THIADIAZOLE NUCLEUS 
                                         
S
N N
 
                                          1,3,4- Thiadiazole 
                                                 
                                                       
 
 
 
 
SYNTHETIC INVESTIGATION 
                         The  Synthesis involves following Mechanism 
 First Step Involves the Synthesis of 2-Amino 5-Phenyl 1, 3, 4-Thiadiazole Which is 
accomplished by Cyclization of Thiosemicarbazide in Presence of Phosphorous oxy 
chloride / Suitable dehydrating agent. [Shmeiss et al., 2002, Sankar et al., 2011.]
 
Which is further converted in to imines by the treatment with various substituted 
Aldehydes. 
Final Compounds were Synthesized by Staudinger Imines reaction of Schiff bases 
[Solak and Rollas 2006]. 
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SYNTHETIC SCHEME:- 
  
   STEP1:- 2-Amino 5-substituted acid 1,3,4-thiadiazole: 
  
O
OH R +  NH2 NH
NH2
S
    POCl3                  
S
N N
NH2R
 
       Acid               Thiosemicarbazide                              2-amino 5-Substituted 1, 3, 4, 
thiadiazole 
STEP2:-5[substituted]phenyl-N-[1E]-[substituted] phenyl methylene]-1,3,4 
thiadiazol-2-amine:- 
        
S
N N
NH2R
 
O
R
            
S
N N
R
N
R
1
               
                                                 4-6 hours/ Ethanol Reflux                                                                                
 2-amino 5-Substituted 1, 3, 4, thiadiazole 
 
STEP1:-2-Amino 5-substituted acid 1,3,4-thiadiazole:
(70) 
          A equimolar mixture of Aromatic carboxylic acid (0.1mole) and 
Thiosemicarbazide (0.1mole), in POCl3 (excess), was refluxed for one hour, Crushed 
ice (90ml) was added to the reaction mixture and again refluxed for another 4 hour, 
on completion of reaction TLC was monitored, cool to room temperature and filter, 
the filtrate was neutralized by saturated potassium hydroxide solution, filter, dried 
and recrystallised from suitable solvent. 
 
 STEP2:  5[substituted]phenyl-N-[1E]-[substituted] phenyl methylene]-1,3,4 
thiadiazol-2-amine:
(67,69) 
           An equimolar quantity of 2-amino 5-substituted 1,3,4-thiadiazole [0.01mole] 
was added to various Aldehydes [0.01mole] and dissolved in absolute ethanol the 
reaction mixture was refluxed for 4-6 hours on completion of reaction was monitored 
by TLC, cool to room temperature and pouring ice product was formed ,filter, dried 
and  recrystallised using ethanol. 
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Acids used[R]:-  
 Benzoic Acid 
 Phenoxy Acetic Acid 
 Hippuric Acid. 
 
Aldehyde used[R1]:- 
 2-Hydroxyl Benzaldehyde 
 4- Hydroxyl Benzaldehyde 
 2,4-dichloro Benzaldehyde 
 3-Nitro   Benzaldehyde 
    MECHANISM: 
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4.5 REACTANT PROFILE
(73)
 
BENZOIC ACID:-
 
                                    
O
OH
                         
Synonym                     : Benzene Carboxylic acid 
Molecular Formula    :  C7H6O2 
Molecular weight       : 122.12 
Description                 : White Crystalline Solid 
Melting point              : 171ºc 
Solubility                    :  Chloroform [Slightly], Methanol [Slightly]. 
THIOSEMICARBAZIDE:- 
                   NH2 NH
S
NH2
 
Synonym: Thiocarbamoyl hydrazide                           
Molecular Formula: CH5N3S 
Molecular Weight   : 91.132 
Description            : white crystalline powder 
Melting point          : 180-183ºc 
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PHENOXY ACETIC ACID: 
                                 
O O
OH 
Synonym: Glycolic acid Phenyl ether  
Molecular Formula: C8H8O3 
Molecular weight: 152.14 
Description    : Colorless needle-like crystal 
Melting point:  100ºc 
Solubility       :  water 
HIPPURIC ACID: 
          
NH
O
O
OH
 
Synonym     : N-Benzoyl glycine 
Molecular Formula: C9H9NO3 
Molecular weight: 179.179 
Description    : white powder 
Melting point: 187 to 188ºc 
Solubility      : Hot water 
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4-HYDROXYL BEZALDEHYDE:- 
                                                 
O
OH  
 Synonym:     Para hydroxyl benzaldehyde                    
Molecular Formula: C7H6O2 
Molecular weight:   121.12 
Description            : Light yellowish to light brown  
Melting point        :   191ºc 
2, 4 DICHLORO BENZALDEHYDE:- 
                         
O
Cl
Cl  
Molecular Formula: C7H4Cl2O 
Molecular weight   : 175.01 
Description            : white crystalline solid 
Melting point        :  233ºc 
Solubility              : Water/ Ethanol 
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3-NITRO BENZALDEHYDE:- 
                                               
O
N
+
O
-
O
                               
Synonym: M-Nitrobenzaldehyde 
Molecular Formula: C7H5NO3 
Molecular weight: 151.02 
Description        :  Yellowish to brownish crystalline 
Melting point     : 55-57ºc 
Solubility            : Ethanol. 
2-HYDROXY BENZALDEHYDE:- 
                             
O
OH
 
Molecular Formula:   C7H6O2 
Molecular weight:      122.12 
Description        :    Colorless or pale yellow 
Boling Point        : 196 to 197ºc 
Solubility             : Ethanol 
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SYNTHESIS OF COMPOUNDS:- 
N
S
N
NH2
R  
  
N
S
N
N
OH
 
N
S
N
N
OH
 
N
S
N
N
N
+
O
-
O
 
O S
N
N
NH2
 
NH
O
S
N N
NH2
 
N
S
N
N
Cl
Cl
 
                                                                                         .                                                                                                                                                                                                                                                                               
2 Amine 5-Substituted acids  Reacts With 
  Step1:  Benzoic acid [Intermediate for 2
nd 
Step]. 
              Phenoxy acetic acid 
               Hippuric acid. 
  Step2: 
              2-amino 5- Phenyl 1,3, 4 Thiadiazole Reacts with  
              2-Hydroxyl Benzaldehyde 
             4-Hydroxyl Benzaldehyde 
              2,4 Dichloro Benzaldehyde 
               3-Nitro Benzaldehyde. 
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    4.6METHODS OF IDENTIFICATION:-                                                                                                                                                                     
 Melting point 
 TLC 
 Infra red Spectroscopy 
 Nuclear Magnetic Resonace 
 Mass Spectroscopy.  
          The synthesized compounds were identified by using following method 
 Melting point:- 
          The melting point of the compounds is determined by the capillary tube 
method. The synthesized compounds were start losing their crystallinity at a 
particular temperature. 
 
Thin layer chromatography:-  
          Pre-coated TLC plates with silica gel GF 250 are used. Samples of reactants 
and products are prepared with suitable solvents.  
          The characterization was carried out using sophisticated methods like Infra-red 
spectroscopy, Nuclear magnetic resonance spectroscopy and Mass spectroscopy. 
 
Infrared Spectroscopy:- 
(58) 
          The infrared spectroscopy is one of the most powerful analytical techniques, 
this offers the possibility of chemical identification. The most important advantages 
of infrared spectroscopy over the other usual methods of structural analysis are that it 
provides useful information about the functional groups present in the molecule 
quickly. The technique is based upon the simple fact that a chemical substance shows 
marked selectable absorption in the infrared region. After absorbing IR radiations the 
molecules of a chemical compound exhibit small vibrations, giving rise to closely 
packed absorption bands called as IR absorption spectrum which may extend over a 
wide wavelength range. Various bands will be present in IR spectrum which 
corresponds to the characteristic functional groups and bonds present in a chemical 
substance. Thus an IR spectrum of a chemical compound is a fingerprint for its 
identification. The infrared spectrum of the prepared derivatives were taken by using 
Avatar 330Thermo Nicolet FT-IR spectrometer and Jasco 460 plus FT-IR 
spectrophotometer using potassium bromide pellet technique 
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Nuclear Magnetic Resonance Spectroscopy: 
            It is the branch of spectroscopy in which radiofrequency waves induces 
transitions between magnetic energy levels of nuclei of a molecule. The magnetic 
energy levels are created by keeping nuclei in a magnetic field. Without the magnetic 
field the spin states of nuclei are degenerated i. e., possess the same energy and the 
energy level transition is not possible. The energy level transition is possible with the 
application of external magnetic field which requires different Rf radiation to put 
them into resonance. This is a measurable phenomenon. It is a powerful tool for the 
investigation of nuclei structure. 1HNMR and 13CNMR Spectras of the prepared 
derivatives were done by using 400-MHz and 500-MHzBruker spectrometer using 
internal standard as tetra methyl silane. 1H and 13C NMR Spectral were taken with 
dimethyl sulphoxide (DMSO) as a solvent and the data of chemical shift were shown 
as delta values related to trimethylsilane (TM) in ppm. 
 
Mass spectroscopy 
(58) 
            Mass spectrometer performs three essential functions. First, it subjects 
molecules to bombardment by a stream of more amounts of energy electrons, 
converting some of the molecules to ions, which are then accelerated in a field of 
electric. Second, the ions which are accelerated are divided according to their ratios 
of mass to charge in an electric or magnetic field. Finally the ions that have particular 
mass-to-charge ratio are detected by a device which can count the number of ions 
striking it. The detector’s output is amplified and fed to a recorder. The trace from the 
recorder is a mass spectrum a graph of particles detected as a function of mass-to-
charge ratio. The Mass of the synthesized compound was taken using Agilent (1100 
MSD) spectrometer instrument. 
 
HYPHENATED TECHNIQUES:- 
 
GC-MS: - To determine the mass and also get an idea about the purity of the sample. 
LC-MS: - When the sample cannot be vaporized, GC-MS cannot be performed. So 
LC-MS is performed. 
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4.7 MICROBIOLOGICAL ASSAY: 
(74-77) 
           Microbial assays or microbiological assays is a type of bioassay and are 
designed to analyze the compounds or substances which have effect on 
microorganisms. Microbiological assay is defined as the determination or estimation 
of concentration or potency of an antibiotic by means of measuring and comparing 
the area of zone of inhibition or turbidity produced by test substance with that of 
standard over a suitable microbe under standard conditions. So as definition says the 
hypothesis is that when an antibiotic is administered, there is inhibition in the growth 
of microbe as indicated by decrease in area of zone of microbial colony on nutrition 
media or decrease in turbidity due to decrease in microbial concentration.
 
TYPES OF MICROBIOLOGICAL ASSAY:-
 
REDOX BASED METHODS: 
             Micro plate Alamar blue assay, Resazurin Microtitre Assay, REMA, or Micro 
dilution Resazurin Assay, MRA. Tetrazolium Dyes, Tetrazolium Micro plate Assay, 
TEMA. 
REPORTER GENE-BASED METHODS: 
             Green Fluorescent protein Micro plate Assay, GFPMA, Luciferase Assays, 
Beta-Galactosidase Assays. 
OTHER METHODS: BACTEC 460 TB 
              Nitrate Reductase Assay, NRA. Disk Diffusion, Visual Micro broth, or Broth 
Micro dilution, Malachite Green, STC Agar, Flow cytometer. 
MICROPLATE ALAMAR BLUE ASSAY:- 
METHOD:  Micro plate Alamar Blue Assay [MABA] 
PREPARATION OF INOCULUMS: 100µl of the Middle brook 7H9 broth.   
REQ UIREMENTS: 96 wells plate, Para film [all are sterilized by dry heat]. 
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NUTRIENT MEDIUM:  25µl of freshly prepared 1:1 mixture of Alamar Blue 
reagent and 10% tween 80 
WORKING PROCEDURE:  
          Stock solutions of the synthesized compounds and standard drug used were 
prepared in sterile deionized water and taken in the concentration of 0.1 to 100µl/ml. 
200µl of sterile deionized water was added to all outer perimeter wells of sterile 96 
wells plate to minimized evaporation of medium in the test wells during incubation. 
The 96 wells plate received 100µl of the Middle brook 7H9 broth and serial dilutions 
of compounds were made directly on plate.  The final drug concentrations were tested 
were 100 to 0.2µg/ml.  Plates were covered and sealed with Para film and incubated 
at 37 c for five days.  After this time, 25 l of   freshly prepared 1:1 mixture of 
Alamar Blue reagent and 10% tween 80 was added to the plate and incubated for 
24hrs.  A blue color in the well was interpreted as no bacterial growth, and pink color 
was scored as growth. The MIC was defined as lowest drug concentration which 
prevented the color change from blue to pink.
 (79, 80)
 
CHEMISTRY :- 
( 78) 
O
N
O
O
Na
O
O
N
O
O
Na
 
ADVANTAGES:-  
 It involves no cell lysis. 
 It is non-toxic 
 It has high sensitivity and linearity. 
APPLICATION: 
(81) 
 Especially meant for studies on Mycobacterium tuberculosis. 
 Used extensively in cell Viability and Cytotoxicity Studies. 
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4.9 IN SILICO PREDICTION: - 
(71, 72)
       
        In silico toxicity prediction was done using OSIRIS Property Explorer. It is free 
software available for access in the Organic Chemistry Portal. Using this prediction 
tool, mutagenicity, tumerogenicity, skin irritation and reproductive effects can be 
calculated. The prediction properties relies on a precompiled set of structure fragment 
that gives rises to toxicity alerts in case they are encountered in the structure currently 
drawn. These fragment lists is created by rigorously shredding all compounds in the 
data base known to be active in a certain toxicity class. During the shredding any 
molecule is first cut at every rotatable bonds leading to a set of core fragments.  
       The designed and docked molecules are screened in silico using 
MOLINSPIRATION Cheminformatics software to evaluate drug likeness. This tool 
is quick and easy to use. It is a software available online for calculation of important 
molecular properties logP, polar surface area, number of hydrogen bond donors and 
acceptors and others, as well as prediction of bioavailability score for the most 
important drug targets(GPCR ligands,  Kinase inhibitors, ion channel modulators, 
nuclear receptors).  
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INSILICO PREDICTION OF DRUG LIKENESS:- 
           Cheminformatics software to evaluate drug likeness. This tool is quick and 
easy to use. It is a software available online for calculation of important molecular 
properties logP, polar surface area, number of  hydrogen bond donors  and acceptors 
and others, as well as prediction of bioavailability score for the most important drug  
 
TABLE NO: 1 LIPINSKI RULE AND SYNTHESIZED COMPOUNDS 
Sample 
code 
Logp TPSA Number of 
non-
hydrogen 
atom 
Molecular 
weight 
No of 
Hydrogen 
bond 
Acceptor 
No of 
Hydrogen 
bond 
donors 
No of rule 
5 
Violation 
No of 
rotable 
bonds 
Molar 
volume 
SDK1 3.63 58.38 20 281.34 4 1 0 3 240.54 
SDK2 3.63 58.38 20 281.34 4 1 0 3 240.54 
SDK3 5.39 38.15 21 334.23 3 0 0 3 259.59 
SDK5 4.04 83.97 22 310.34 5 0 0 4 255.85 
PAA 1.52 61.04 14 207.26 4 2 0 3 174.93 
HA 1.15 80.91 15 220.2 5 3 0 2 180.53 
 
Where, 
TPSA - Total polar surface area. 
Thus the proposed compounds have satisfied all the above three filtering methods of 
good predictive activity, good docking scores and also drug like properties and that 
these molecules are accepted to be orally bioavailable. 
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RESULTS OF DRUG DESIGN:- 
DOCKING:- 
        Two hundred molecules, which are Sketched using Chem Sketch, were docked 
against the MTB enzyme. Decaprenylphosphoryl-beta-D-ribose 2’-epimerase-1 by 
using Argus lab 4.0.1 Software. The molecules with best docking Score and good 
interactions were selected and synthesized. 
TABLE: 2 The molecules with good docking score were mentioned as below. 
SAMPL
E CODE 
MOLECULES 
DOCKIN
G SCORE 
kcal/mole 
DOCKING VIEW 
SDK1 N
S
N
N
OH
 
-10.54 
 
SDK2 N
S
N
N
OH 
-11.974 
 
SDK3 N
S
N
N
Cl
Cl 
-11.099 
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SDK5 N
S
N
N
N
+
O
-
O
 
-11.262 
 
 
 
PAA 
O S
N
N
NH2
 
-9.5781 
 
 
HA 
NH
O
S
N N
NH2
 
-8.567 
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INTERACTIONS OF THE DOCKED MOLECULES WITH THE ENZYME 
DPRE1 
TABLE3:- Hydrogen bond Interactions and their Interactions with Amino acid 
SAMPLE 
CODE 
HYDROGEN BOND 
INTERACTION 
INTERACTIONS WITH 
AMINOACIDS 
SDK1 
 
 
 
SDK2 
  
SDK3 
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SDK5 
 
 
PAA 
 
 
 
 
 
HA 
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INSILICO TOXICITY PREDICTION:-                                                           
           All the data set molecules were subjected to the toxicity risk Assessment by 
using Osiris program, which is available online free of cost. The OSIRIS property 
Explorer shown in this page is an integral part of Acetilon in house substance 
registration system. It allows drawing chemical structures and also calculates drug 
relevant properties whenever a structure is valid. Prediction results are color coded in 
which the red color shows high risks with undesired effects  like mutagenicity or a 
poor intestinal absorption and green color indicates drug-conform behavior. 
Molecular property prediction:- 
 Toxicity prediction  
 Clog P Prediction 
 Solubility prediction 
 Molecular weight 
TABLE NO: - 4 
SAMPLES SDK1 SDK2 SDK3 SDK5 PAA HA 
MUTAGENIC + + + + + + 
TUMORIGENIC + + + + + + 
IRRITANT + + + + + + 
REPRODUCTIVE 
EFFECT 
+ + + + + + 
[+] indicates absence of toxicity. 
[-] indicates Presence of toxicity. 
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                                                  Fig. SDK1 
 
 
 
                                                              Fig.SDK2 
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                                                         Fig. SDK3 
 
                                        
                                                      Fig. SDK5 
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                                                      Fig. PAA 
 
                                                          Fig. HA 
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RESULTS OF SYNTHETIC EFFORTS:- 
                          The Synthetis was Performed by the conventional method. The 
reaction was carried out by using 0.1 mole of Benzoic acid of substituted aromatic 
aldehyde and ethanol acts as catalyst the mixture was refluxed.  This leads to the 
formation of thiadiazole nucleus. 
TLC PROFILE:- 
                            Thin layer chromatography (TLC) was done on silica gel pre coated 
plates (604GF 254Merck) with a suitable solvent system. The Rf values were 
recorded accordingly. This technique is widely employed for the identification of the 
organic compounds with characteristic Rf values. This method is also applied to 
determine the progress of the reaction, to examine the purity of the end product. After 
the development of chromatogram, the spots were detected by placing the plate in UV 
chamber. In all the synthesized derivatives, single spots were seen, indicating the 
purity of the compound. 
TABLE NO: 5 
RESULTS OF SYNTHETIC EFFORTS:- 
 
 
 
Compound      
code 
Molecular 
weight 
Melting 
point 
Rf value Percentage yield 
SDK1 281.33 222 0.42 81% 
SDK2 281.33 222 0.37 83% 
SDK3 334.22 230 0.38 80% 
SDK5 310.33 228 0.35 77% 
HA 207.25 148 0.28 70% 
PAA 219.25 151 0.32 68% 
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RESULTS OF SCHEMES:- 
COMPOUND CODE: - SDK1 
                          
N
S
N N
OH
 
Physicochemical Properties of 2-{(E)-[(5-phenyl-1, 3, 4-thiadiazol-2-yl) imino] 
methyl} phenol 
Molecular Formula: C15H11N3OS 
Formula weight      : 281.33234 
Composition           : C [64.04%], H [3.94%], N [14.94%], O [5.69%], S [11.40%]. 
Appearance            : Yellow in Color 
Solubility               : Soluble in Ethanol, Methanol. 
Molar Refractivity:  81.85+ 0.5cm 
Molar Volume     :    214.4+7.0cm 
Parachor                :  583.5+8.0cm 
Index of Refraction: 1.688+ 0.55 
Surface Tension    :  54.7+7.0dyne/cm 
Density                 :  1.31+0.1g/cm 
Polarizability       :   32.44+0.5cm 
Monoisotopic Mass: 281.0622Da 
Nominal Mass   :    281Da 
Average Mass:     281.3323Da 
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SAMPLE CODE: SDK2 
Physicochemical properties of 4-{(E)-[(5-phenyl-1, 3, 4-thiadiazol-2-yl) imino] 
methyl} Phenol 
                            
N
S
N N
OH
   
Molecular Formula: C15H11N3OS 
Formula weight      : 281.33234 
Composition           : C [64.04%], H [3.94%], N [14.94%], O[5.69%],S[11.40%]. 
Appearance            : Yellow in Color 
Melting point        : 222ºC 
Solubility               : Soluble in Ethanol, Methanol. 
Molar Refractivity:  81.85+ 0.5cm 
Molar Volume     :    214.4+7.0cm 
Parachor                :  583.5+8.0cm 
Index of Refraction: 1.688+ 0.55 
Surface Tension    :  54.7+7.0dyne/cm 
Density                 :  1.31+0.1g/cm 
Polarizability       :   32.44+0.5cm 
Monoisotopic Mass: 281.0622Da 
Nominal Mass:         281Da 
Average Mass:         281.3323Da 
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SAMPLE CODE: SDK3 
                 Physicochemical properties of (E)-1-(2, 4 – dichlorophenyl) -N-(5-
phenyl-1, 3, 4-thiadiazol-2-yl) methanimine 
                         
N
S
N N
Cl
Cl
 
Molecular Formula: C15H9Cl2N3S 
Formula weight      : 334.22 
Composition           : C (53.90%), H (2.71%), C (21.22%), N(12.57%), S(9.59%). 
Appearance            : Yellow in Color 
Melting point        : 230ºC 
Solubility               : Soluble in Ethanol, Methanol. 
Molar Refractivity: 90.20± 0.5cm
3
 
Molar Volume     :   235.8± 7.0cm
3
  
Parachor                :  635.5± 8.0cm
3
 
Index of Refraction: 1.60± 0.05cm
3 
Surface Tension    :  52.7 ± 7.0 dyne/ cm 
Density                 :  1.41± 0.1 g/cm
3
 
Polarizability       : 35.72  0.5 10-24cm3 
Monoisotopic Mass: 332.983 Da 
Nominal Mass:   333Da       
Average Mass:  334.2231Da     
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SAMPLE CODE: SDK5      
               Physico chemical properties of (E)-1-(3-nitrophenyl)-N-(5-phenyl-1, 3, 
4-thiadiazol-2-yl) methanimine 
                                     
N
S
N N
N
+
O
-
O
 
Molecular Formula: C15H10N4O2S 
Formula weight      : 310.3305 
Composition           : C (58.05%), H (3.25%),N(18.05%),O(10.31%),S(10.33%) 
Melting point        : 228ºC 
Solubility               : Soluble in Ethanol, Methanol. 
Molar Refractivity: 86.66±0.5cm
3 
Molar Volume     : 222.5±7.0cm
3 
Parachor                :  623.3±8.0cm
3
 
Index of Refraction: 1.706±0.05
 
Surface Tension    :  61.5±7.0dyne/cm 
Density                 :  1.39±0.1g/cm
3
 
Polarizability       : 34.35±0.5 10-24cm
3 
Monoisotopic Mass: 310.052466 Da 
Nominal Mass:  310 Da 
Average Mass:  310.3305 Da  
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SAMPLE CODE: PAA 
Physicochemical Properties of 5-(Phenoxy methyl)-1, 3, 4- thiadiazol-2-amine   
                 
O S
N
N
NH2
  
Molecular Formula: C9H9N3OS 
Formula weight      : 207.25226 
Composition          : C (52.16%), H (4.38%), N (20.27%), O (7.72%), S (15.47%). 
Melting point           : 148ºc 
 Solubility               : Soluble in Ethanol, Methanol. 
Molar Refractivity:  56.22±0.3cm
3
 
Molar Volume     :   152.3±3.0cm
3 
Parachor                :  4.33.3±4.0cm
3 
Index of Refraction: 1.659±0.02 
Surface Tension    :  6.54±3.0dyne/cm 
Density                 :  1.360±0.06g/cm
3 
Polarizability       : 22.28±0.5 10-24cm
3 
Monoisotopic Mass: 207.0466Da 
Nominal Mass:   207Da 
Average Mass:  207.2523Da 
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SAMPLE CODE: HA 
Physicochemical properties of N-(5-amino-1, 3, 4-thiadiazol-2-yl) benzamide 
                       
NH
O
S
N N
NH2
 
Molecular Formula: C9H8N4OS 
Formula weight      : 220.25 
Composition           : C (49.08%), H (3.66%), N (25.44%), O (7.26%), S (14.56%). 
Melting point        : 151ºC 
Solubility               : Soluble in Ethanol, Methanol. 
Molar Refractivity: 59.63±0.3 cm
3
 
Molar Volume     :  146.5±3.0 cm
3
  
Parachor                :  444.1± 4.0cm
3 
Index of Refraction: 1.749± 0.02
 
Surface Tension    :  84.4±3.0 dyne/ cm 
Density                 :  1.503± 0.06 g/cm
3 
Polarizability       : 23.63±0.5 10-24 cm
3 
Monoisotopic Mass: 220.04 Da 
Nominal Mass:  220 Da     
Average Mass:   220.251 Da  
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CHARACTERIZATION: 
                                    The newly synthesized compounds were characterized by 
o IR 
o NMR 
o GC-MS, LC-MS 
IR SPECTROSCOPY:- 
               The Samples were prepared by the KBr Pellet technique and Spectrum 
obtained from ABB [MB 3000] Spectrophotometer 
             The Spectra were examined for the absence of the functional group region of 
parent compound and examined for presence of the Vibrational absorption band for 
the new functional group. 
             Our reaction involves reaction between Aldehyde and amine to yield Schiff 
bases. 
             The absorption bands for aldehyde are 
 2800-2700cm-1 
 1700-1750 cm-1 
              The absorption band for amine 3400-3600cm
-1 
             The absorption of newly Synthesized –C=N is 1650-1600cm-1. 
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IR ABSORPTION BAND:- 
The infrared spectroscopy is one of the most powerful analytical techniques; this 
offers the possibility of chemical identification. The most important advantages of 
infrared spectroscopy over the other usual methods of structural analysis are that it 
provides useful information about the functional groups present in the molecule 
quickly. 
TABLE NO: - 6 
ABSORPTION BAND SDK1 SDK2 SDK3 SDK5 PAA HA 
NH Stretching     ×     ×    ×    ×   
  
CH Stretching   
          
OH Stretching   
  
     ×  ×  ×  × 
C=N Stretching    
      
  ×   × 
C-C Stretching   
          
C-S-C bending   
      
    ×    × 
 
The presence of stretching and or bending for the new functional group and the 
absence of the stretching and or bending motion for the parent functional groups 
undergoing the change is indicative of the successful formation of the expected 
compound. 
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SAMPLE CODE: - SDK1 
 
                                            TABLE NO: 7 
S.NO FUNCTIONAL GROUP REGION WAVE NUMBER( cm
-
1) 
1. C-H Stretching 3085.88 cm
-1 
2. Aliphatic C-H Stretching 2931.88 cm
-1 
3. OH Stretching 3440.78 cm
-1 
4. C=N Stretching 1627.80 cm
-1 
5. C-S-C Bending 756.04  cm
-1 
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SAMPLE CODE: SDK2 
 
                                   TABLE NO: 8 
S.NO FUNCTIONAL GROUP REGION WAVE NUMBER( cm
-
1) 
1. Aromatic C-H Stretching 2923.87 cm
-1 
2. Aliphatic C-H Stretching 2854.44 cm
-1 
2. OH Stretching 3440.76 cm
-1 
3. C=N Stretching 1627.80 cm
-1 
4. C-S-C Bending 756.04  cm
-1 
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SAMPLE CODE: SDK3 
 
                                           TABLE NO: 9 
S.NO FUNCTIONAL GROUP REGION WAVE NUMBER( cm
-
1) 
1. Aromatic C-H Stretching 3O85.88cm
-1 
2. Aliphatic C-H Stretching 2962.44 cm
-1 
3. C=N Stretching 1635.52 cm
-1 
4. C-S-C Bending 756.04  cm
-1 
5. C=C Stretching 1610.33 cm
-1 
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  SAMPLE CODE:-SDK7 
 
                                          TABLE NO: 10 
S.NO FUNCTIONAL GROUP REGION WAVE NUMBER( cm
-
1) 
1. Aromatic C-H Stretching 3O85.88cm
-1 
2. Aliphatic C-H Stretching 2962.44 cm
-1 
3. C=N Stretching 1635.52 cm
-1 
4. C-S-C Bending 756.04  cm
-1 
5. N=O Stretching 1512.08 cm
-1 
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SAMPLE CODE: - PAA 
 
                                            TABLE NO: 11 
S.NO FUNCTIONAL GROUP REGION WAVE NUMBER( cm
-
1) 
1. Aromatic C-H Stretching 3105.88cm
-1 
2. Aliphatic C-H Stretching 2707.86 cm
-1 
3. N-H Stretching 3271.03cm
-1 
4. C-S-C Bending 624.04  cm
-1 
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SAMPLE CODE: HA 
 
                                          TABLE NO: 12 
S.NO FUNCTIONAL GROUP REGION WAVE NUMBER( cm
-
1) 
1. Aromatic C-H Stretching 3070.88cm
-1 
2. Aliphatic C-H Stretching 2831.86 cm
-1 
3. N-Stretching 3247.03cm
-1 
4. C-S-C Bending 954.04  cm
-1 
5. C=O Stretching 1643.23 cm
-1 
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NMR SPECTROSCOPY: 
                                       It is a powerful tool for the investigation of nuclei structure. 
1HNMR Spectra’s of the prepared derivatives were done by using 400-MHz and 500-
MHzBruker spectrometer using internal standard as tetra methyl silane. 
1
 H NMR SPECTRAL DATA OF THE SYNTHESIZED COMPOINDS: 
 
 
TABLE NO:-13 
S.NO DELTA VALUE TYPE OF PEAK NUMBER OF PROTON 
1. 7.42-7.484 Multiplet 6 protons 
2. 7.596 Doublet 2Protons 
3. 7.74-7.766 Triplet 3Protons 
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SAMPLE CODE: SDK2 
 
                                           TABLE NO: 14 
 
  
S.NO DELTA VALUE TYPE OF PEAK NUMBER OF PROTON 
1. 7.42-7.484 Multiplet 6 protons 
2. 7.596 Singlet 1Protons 
3. 7.74-7.766 Triplet 3Protons 
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SAMPLE CODE: SDK3 
 
                                                       TABLE NO: 15 
S.NO DELTA VALUE TYPE OF PEAK NUMBER OF PROTON 
1. 10.284-10.285 Singlet 1Protons 
2. 7.417-7.496 Quarteret 4 Protons 
3. 7.628-7.654 Doublet 1 Protons 
4. 7.744-7.768 Doublet 1 Protons 
5. 7.862-7.894 Doublet 2 Protons 
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SAMPLE CODE: SDK5 
 
TABLENO: 16 
S.NO DELTA VALUE TYPE OF PEAK NUMBER OF PROTON 
1. 7.207-7.229 Singlet 1 Protons 
2. 7.409-7.490 Multiplet 5 Protons 
3. 7.593-7.620 Singlet 1 Protons 
4. 7.870-7.958 Doublet 2 Protons 
5. 8.011-8.035 Singlet 1 Protons 
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SAMPLE CODE: PAA 
 
TABLE NO: 17 
S.NO  DELTA VALUE TYPE OF PEAK NUMBER OF PROTON 
1. 6.965-7.045 Doublet 2 
2. 7.295-7.332 Doublet 2 
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SAMPLE CODE: HA 
 
                                               TABLE NO: - 18 
S.NO DELTA VALUE TYPE OF PEAK NUMBER OF PROTON 
1. 6.976-7.324 Singlet 1 
2. 7.436-7.474 Triplet 3 
3. 7.623-8.193 Doublet 2 
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MASS SPECTROMETRY:- 
                                                Mass Spectrometry is to determine the molecular 
weight of the Synthesized Compounds. 
HYPHENATED TECHNIQUES:- 
GC-MS: - To determine the mass and also get an idea about the purity of the sample. 
LC-MS: - When the sample cannot be vaporized, GC-MS cannot be performed. So 
LC-MS is performed. 
MASS SPECTRA DATA OF THE SYNTHESISED COMPOUNDS:- 
                               TABLE NO:-19 
COMPOUND 
CODE 
MASS SPECTRA  DATA  OF THE  
SYNTHESISED COMPOUNDS 
MOLECULAR 
WEIGHT 
SDK1 281.25 281.25 
SDK2 281.25 281.25 
SDK3 334.42 334.42 
SDK5 310.34 309.34 
PAA 207.12 207.12 
HA 219.03 218.03 
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  GC-MS 
  SAMPLE CODE: SDK1 
Fig.22 GC-MS Spectral data of the sample SDK1 
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GC-MS 
SAMPLE CODE: PAA 
Fig.23 GC-MS Spectral data of Sample PAA 
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LC-MS 
SAMPLE CODE: SDK3 
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SAMPLE CODE: HA 
 
RESULTS AND  DISCUSSION 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 100 
 
 
 
RESULTS AND  DISCUSSION 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 101 
 
 
BIOLOGICAL SCREENING:- 
The Synthesized compounds were screened for their in-vitro anti 
mycobacterial activity by means of Alamar blue assay. The compounds were tested in 
the concentration range of 100 to 0.8µg/ml against M.tuberculosis H37RV Strain 
grown in Middle brook 7H9 broth in 96 well titre plates. Pyrazinamide-3.125µg/ml 
and Streptomycin-6.25µg/ml were used as standards for comparison. A blue color in 
the well was interpreted as no bacterial growth so it is termed as sensitive, and pink 
color was scored as growth and is referred as resistant. The MIC was defined as 
lowest drug concentration which prevented the color change from blue to pink 
                 TABLE NO: 20   DOCKING SCORE WITH MIC VALUE 
COMPOUND DOCKING SCORE(kcal/mol) 
MIC VALUE 
Mcg/ml 
SDK3 --12.73 3.12 
SDK5 -11.32 3.12 
SDK2 -10.82 6.25 
SDK1 -10.82 6.25 
HA -9.146 12.5 
PAA -8.537 12.5 
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MABA REPORT OF THE SYNTHESISED COMPOUNDS: 
All the synthesized compounds showed anti-mycobacterial activity in a 
varying degree against the organism tested. The organism tested was susceptible to all 
the synthesized compounds and the minimum inhibitory concentration for the 
compounds varied between 6.25 and 3.125 mcg/ml. The data pertaining to these 
observations are presented in the table. Inhibition was compared using as Standard. 
Pyrazinamide- 3.125 mcg/ml Streptomycin- 6.25 mcg/ml Ciprofloxacin- 3.125mcg/ml  
TABLE NO:-21 
SAMPLE CODE 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
SDK1 S S S S S R R R 
SDK2 S S S S S R R R 
SDK3 S S S S S S R R 
 SDK5 S S S S S S R R 
   HA S S S S R R R R 
   PAA S S S S R R R R 
 
NOTE: 
S- Sensitive 
R- Resistant 
Strain used: - M. tuberculosis [H37RV]: ATCC NO-27294. 
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Among the synthesized compounds, compound- SDK1 gave docking Score of -10.82 
and exhibit the activity at 6.25 mcg/ml and compound- SDK2 gave docking Score of 
-10.87 and exhibit the activity at 6.25 mcg/ml and SDK3 gave docking Score of -
12.73 and exhibit the activity at 3.12mcg/ml and also compound SDK5 gave docking 
Score of -11.32 and exhibit the activity at 3.12mcg/ml.  
                      Fig SYNTHESIZED COMPOUNDS PHOTOGRAPH 
                                         
Fig   STANDARD DRUG PHOTOGRAPH 
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COMPARATIVE STUDY OF DOCKING SCORE FOR DIFFERENT 
TARGET:- 
                     Nearly 100 molecules were sketched using chem sketch, and the 
molecules were docked against the MTB enzyme using Argus Lab 4.0.1 software.  
The following molecules were docked against different targets and the molecules with 
best docking score and good interaction were selected and synthesised.    
                      The molecules were also docked against the following five targets 
1. Glutamine Synthetase I  
2. Methoxy Mycolic acid Synthase II  
3. Cyclopropane Mycolic Acid Synthase II  
4. L, D-Transpeptidase  
5. Decaprenyl Phosphoryl-b-d-Ribose2’-Epimerase I (DprEI) 
                                 TABLE NO: 22 Argus Lab Software (4.0.1) 
S.NO 
NAME OF THE 
ENZYMES 
DOCKING SCORE 
SDK1 SDK2 SDK3 SDK5 PAA HA 
1. DecaprenylPhosphory 
Beta-D-ribose-2 
Epimerase 
-
10.43 
-
10.83 
-
11.69 
-
11.34 
-8.57 -9.54 
2. Cyclopropane Mycolic 
acid Synthase-II 
-
10.32 
-
10.23 
-
11.45 
-
11.34 
-8.65 -8.32 
3. Methoxy Mycolic  acid  
Synthase-II 
-
10.87 
-
10.56 
-
11.93 
-
10.54 
-9.43 -8.34 
4. Glutamine  Synthetase-I -
10.78 
-
10.76 
-
11.87 
-
11.54 
-9.54 -8.54 
5. L&D Transpeptidase -
10.56 
-
10.34 
-
11.54 
-
11.75 
-9.87 -8.75 
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  It is concluded that Decaprenylphosporyl-beta-D ribose-2 epimerase has best 
Docking score among different targets. So the fine tuning the structures of these 
compounds will yield molecules with better anti mycobacterial activity. Against the 
Pathogen. 
DISCUSSION 
i) The following compounds have best docking score against specific targets and 
were synthesized in an  appropriate manner . The purity of the compounds 
were determined, They exhibited sharp melting point and  single spot obtained 
in the TLC.  
ii)  Of the six compounds, five of them were obtained at 98% purity. It was 
confirmed by GC-MS analysis (obtaining a single peak) and molecular weight 
also obtained at ± 1 variation. Then the functional group determination was 
obtained from FT-IR. It was confirmed by obtaining   specific absorption band 
in the spectra. .  
iii) The biological evaluation of the compounds is denoted that the specific 
organism was sensitive at 3.12 and 3.12mcg/ml and showed better activity 
compared to standard drugs.  
iv) The toxicity of the compounds also showed that all the 6 compounds are non-
toxic. 
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SUMMARY 
 Decaprenylphosphoryl-beta-D-ribose 2-epimerase a critical enzyme for the growth of 
Mycobacterium tuberculosis was chosen for our study after review of literature. It 
belongs to the Oxidoreductase family. 
 A database of 200 molecules with high prospects of inhibiting the target Dpre1 were 
carefully chosen by making changes to the known hit molecules, here the thiadiazole 
nucleus was chosen. 
 Selected molecules were designed and docked against Dpre1 using Argus lab® 
software. 
 Six molecules with good docking score [lower binding energy] and interactions were 
shortlisted for synthesis. Reaction conditions were optimized. 
 The selected molecules were subjected to toxicity prediction assessment by OSIRIS® 
property explorer developed by Acetilon Pharmaceuticals limited which is available 
online. The results are color coded as green color which predicts the drug likeness and 
possibly better activity. 
 The molecules were labelled as SDK1, SDK2, SDK3, SDK5, PAA, HA, and were 
synthesized with satisfactory yield. 
 The purity of the synthesized compounds was ensured by repeated recrystallization. 
Further the compounds were evaluated by TLC and Melting point determination. 
 The characterization of the synthesized compounds was done using Infra-red, Nuclear 
Magnetic Resonance [H1 NMR] and Mass spectrometric methods [LC-MS, GC-MS]. 
 All the Synthesized compounds exhibited molecular ion peak (M+) of varying 
intensities. 
 The final pure compounds were screened for Anti-mycobacterial activity by in vitro 
method called Micro plate Alamar Blue Assay [MABA]. 
 The synthesized compounds showed sensitivity [Minimum inhibitory concentration] 
at 3.12mcg/ml. The standard drugs Pyrazinamide, Streptomycin, Ciprofloxacin 
exhibited anti mycobacterial activity at 3.125mcg/ml, 6.25mcg/ml, and 3.125mcg/ml 
concentrations respectively. This indicates that the synthesized compounds are as 
Potent as the standard drugs. 
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                                                   CONCLUSION 
All the compounds gave Docking score between -8.73 to 11.37 kcal/mol 
Pyrazinamide gave docking score 11.55kcal/mol for 4P8Y, Streptomycin gave 
docking score of 10.87kcal/mol for 4P8Y and Ciprofloxacin gave docking score of 
11.25kcal/mol for 4P8Y. There is a correlation between the score and activities of all 
the compounds which were tested and compared with the standard drugs.  This goes 
to prove that Decaprenyl phosphoryl beta-D-ribose 2’ epimerase-1’ (PDBID: 4P8Y) is 
a critical enzyme for anti-mycobacterial activity. So the fine tuning the structures of 
these compounds will yield molecules with better anti mycobacterial activity. Further 
structural modifications of the synthesized compounds will aid in the development of 
potential molecules against the tuberculosis pathogen. 
FUTURE SCOPE OF THE STUDY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 108 
 
FUTURE SCOPE OF THE STUDY:- 
The Synthesized compounds should have significant anti-tubercular activity in 
MABA assay method. Hence the anti-tubercular study would deserve for further 
investigations of in-vivo toxicity and in-vivo anti-tubercular studies. 
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 109 
 
1. Baptise Villemagne, Celine Crauste, Marion Flipo, Alian R. Baulard et.al. Tuberculosis the 
drug development Pipeline at a glance. European Journal of Medicinal Chemistry. 2012; 
51:16. 
2. WWW.tbfacts.org. 
3. Robert Koch., [2008] History of Tuberculosis. 
4. Tuberculosis. World health organization.2010. 
5. Steenken, W., Jr., and I.U. Gardner. 1946. History of h37 Strain of tubercle Bacillus. AM. 
Rev.Tuberc. 54:62-66. 
6. Wilson lg. The historical decline of tuberculosis in Europe and America: its causes and 
siginifance. J hist med alliedsic 1990; 45: 366-96. 
7. http:// tuberculosis. emedtv.com/ tuberculosis-history. 
8. http:// WWW. Medical news today.com/ articles/ 8856.  
9. Hertzberg RP, Pope AJ. High-throughput screening: New technology for the 21st century. 
Curr opin chem boil 2000; 4:445-451. 
10. J Biol Chem. 2002 Mar 29; 277(13):11559-69. Epub 2001 Dec 26.  
 11. Lahana R. How many leads from HTS? Drug Discov Today 1999; 4:447-448.  
12. Brennan PJ, Nikaido H. The envelope of mycobacteria. Annu Rev Biochem. 1995; 64:29- 
63.  
13. McNeil M, Brennan PJ. Structure, function and biogenesis of the cell envelope of 
mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance. Res 
Microbial 1991; 142: 451-463.  
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 110 
 
14. Goyot-Revol V, Innes JA, H ackforth S, Hinks T, Lalvani A. Regulatory T cells are 
expanded in blood and disease sites in patients with tuberculosis. Is J Resp Crit Care Med. 
2006; 173:803-810.  
15. Development of new vaccines and drugs for TB: limitations and potential strategic errors, 
further Microbiology, 2011 February; 6(2):161-177.  
16."Improved data reveals higher global burden of tuberculosis". who.int. 22 October 2014. 
Retrieved 23 October 2014.  
17. World Health Organization (2009). “Epidemiology”. Availability from URL: 
(http://who.int/entity/tb/publications/global-report/2009/pdf/chapter1.pdf).Global 
Tuberculosis control: epidemiology, strategy, and financing.pp.6-33. Accessed  on  10.12.12.  
18. Iademarco MF, Castro KG. Epidemiology of tuberculosis. Semi Respir Infect. 2003; 
18(4):225-240.  
20. http:// tuberculist. epfl.ch/ 
21. Development of new vaccines and drugs for TB: limitations and potential strategic errors, 
further Microbiology, 2011 February; 6(2):161-177. 
22. William O.Foye, Thomas L.Lemke, David A. Williams. Principles of Medicinal 
Chemistry. B.I Waverly Pvt Ltd, New Delhi, 4th ed.1999; 1. 
23. Gareth Thomas. Medicinal Chemistry-An introduction.2
nd
 ed. Willey India Pvt Ltd.2011; 
1. 
24.Zhao, y. h., le, j., Abraham, M.H., Hersey, a., eddershaw, p.j., lus- Suzuki, a., higuchi, w. 
I., ho, n. f., 1970a. 
25. Poulin, p., theil. f.p., 2000. A priori prediction of tissue: plasma partition de waterbeemed, 
h., folkers, g., guy, r. (Eds), pharmacokinetic of drugs to facilitate the use of physiologically-
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 111 
 
based optimization in drug research- biological, physicochemical and pharmacokinetic 
models in drug discovery. J. Pharm. Sci. 89, 16-35. 
26. Udwadia, Z., Amale, R., Ajbani, K., & Rodrigues, C. (2011).13. Gyanshankar Mishra, S 
V Ghorpade, Jasmin Mulani (2014) Totally Drug-Resistant Tuberculosis in India. Oxford 
XDR-TB: An outcome of programmatic management of TB Journals, 201(1). Retrieved April 
3, 2013, from in India. Indian Journal of Medical Ethics 11: 1. 47-52. 
27.Sarah M.Batta, Talat Jabeena, Veemal Bhowrutha, Lee Quilla et.al.,structural basis of 
inhibition of Mycobacterium Tuberculosis DprE1 Benzothiazinone inhibitors. 
28. http://en.wikipedia.org/wiki/Decaprenyl phosphoryl beta-D-ribose-2-epimerase.  
29.Maria Loreto In candela, Elena Perrin, Marco Fanondi, Ana Luisa de Jesus Lopes 
Ribeiro,Giorgia Mori,Alessia Moiana,Maurizio Gramegna, Renato Fani, Giovanna Riccardi 
&Giorgia. International Journal of drug Research and Teachnology.2013; 1(1):26-30. 
30.Mickey Sahu, Sitesh Kumar, Sinha,Krishna Kumar ,Pandey.Computer Aided Drug 
Design:The Most Fundamental Goal is to Predict Whether a Given Molecule Will Bind to a 
Target and if so How Strongly Computer Engineering And Intelligent systems.2013;4(1):45-
47. 
31. Lorenz a Favrot and Donald R Ronning. Targeting the mycobacterial envelope for 
tuberculosis drug development, Expert Rev Anti infect there. 2012; 10[9]:1023. 
32. Sarala Menon, Sujata Dharmshale, Chhaya Chande, ArunaGohil. Drug resistance profiles 
of Mycobacterium tuberculosis isolates to first line anti-tuberculosis drugs. Lung India. 2012; 
29[3]: 227-231. 
33. A.G.Nikalje and P.Mudassar, Multi drug resistant Mycobacterium tuberculosis a brief 
review, Asian Journal of Biological sciences.2011; 4[2]: 101-115. 
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 112 
 
34. Christian Leichardt, Andrew Vernon, Mario C. Raviglione. New drugs and new regimens 
for the treatment of tuberculosis: review of the drug development pipeline and implications 
for national programmes. Current Opinion in Pulmonary Medicine. 2010; 16: 186-193. 
35. Sarah L. Kinnings, Li Xie, Kingston H. Fung, Richard M. Jackson. The Mycobacterium 
tuberculosis Drugome and its Polypharmacological implications, PLOS Computational 
Biology. 2010; 6[11]. 
36. Chinnagiri T.Keerthi Kumar, Jathi Keshavayya,  Tantry N.Rajesh, Sanehalli K. 
Peethambar, Angadi R. Synthesis of some novel 5-Phenyl-1,3,4-thiadiazole 2-amino fused 
azo dye derivatives as potent Antimicrobial agents. International Research Journal of Pure 
and Applied Chemistry. 2011; [3]:119-129. 
37. Jitendra Sainy, Ganesh P. Mishra, Rajesh Sharma, Subhash C. Chaturvedi. Synthesis of 
novel 2-amino 5-Sulfanyl- 1, 3, 4-thiadiazole for Anti Inflammatory and Analgesic agents. 
Pharmaceutical Chemistry Journal. 2009; 43[1]:19-24. 
38. Liu Pattan SR,  Kittur BS, Sastry BS, Thakur DK. Synthesis of some novel 2-amino 5-
substituted 1, 3, 4-thiadiazole for Anti Fungal agents. Indian J. Chem. 2011; 50B, 615-618. 
39 .Foroumadi A, Asadipour A, Mirzaeim, Karimi J, Emamai S. Synthesis Evaluation of 
invitro anti tuberculosis activity of some 2-(5-nitro-2-furyl)-1, 3, 4-thiadiazole derivatives. 
PubMed. 2002; 57(9): 765-769. 
40. Priyabrata Pattanayak.  Rajesh Sharma,   Prasanta Kumar Sahoo.  Synthesis and 
Evaluation of 2-amino 5-Sulfanyl-1, 3, 4-thiadiazole as Antidepressant, Anxiolytic, and 
Anticonvuslant agents. Medicinal Chemistry Research Journal. 2009; (18):351-361. 
41. Dhanya Sunil, Arun M. Isioor,  Prakash Shetty, Satya moorthy K.  Synthesis, 
Characterization Antioxidant and anticancer studies of 6-[3-(4-Chlorophenyl)-1H-Pyrazol-4-
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 113 
 
yl]-3-[2-naphthyloxyl) Methyl][1,2,4]triazolo [3,4-b] [1,3,4] thiadiazole in Hep G2 cell lines. 
Medicinal Chemistry Research Journal. 2011; 20(7):1074-1080. 
42. Stephen Turner, Malcolm Myers, Brian Gadie, Timothy L. Synthesis of Antihypertensive 
of 1, 3, 4-thiadiazole of some 2-aryl 5-guanidino derivatives. Journal of Medicinal Chemistry. 
31(5): 906-13. 
43. Shiradkar M, Kale R. Condensed bridgehead nitrogen heterocyclic systems: microwave 
assisted synthesis and bioactivity of s-triazolo[3,4-b][1,3,4]thiadiazoles, s-triazolo [3,4-
b][1,3,4]thiadiazines and s-triazolo [3’,4’:2,3]-thiadiazino[5,6-b] quinoxaline.  Indian Journal 
of Chemistry. 2005; 45(1): 1009-1013. 
44. Gadad AK, Noolvi MN, Karpoormath RV. Synthesis and antitubercular activity of a 
series of 2-sulfonamido/trifluoromethyl-6-substituted imidazo [2, 1-b]-1, 3, 4-thiadiazole 
derivatives. Bio org Med Chem. 2004; 12(4): 5651-5659. 
45. Palkar MB,  Noolvi MN,  Maddi VS,  Ghatale M,  Nargund LG. Synthesis, spectral 
studies and biological evaluation of novel series of 2-substituted-5,6-diarylsubstituted 
imidazo[2,1-b]-1,3,4-thiadiazole derivatives as possible anti tubercular agents. Medicinal 
Chemistry Research Journal. 2012; 21(1): 1313-1321. 
46. Chitra V, Kumar M, Gupta V. Synthesis and anti tubercular evaluation of imidazo [2, 1-d] 
1, 3, 4 thiadiazole derivatives. Indian Journal of Chemistry. 2005; 45(2): 2234-2239. 
47. Noolvi MN, Patel HM, Navdeep Singh S, Gadad AK . Synthesis and anti tubercular 
evaluation of imidazo [2,1-b] [1,3,4] thiadiazole derivatives. Arabian Journal of Chemistry. 
2013; 54(5): 183-190 
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 114 
 
48. Chinnagiri T.  Keerthi Kumar,  Jathi Keshavayya,  Tantry N. Rajesh Sanehalli K. 
Synthesis, Characterization and Biological Activity of 5-Phenyl-1, 3, 4-thiadiazole 2-
amine.International Journal of Chemistry.2013;6[12]. 
 
49. Zi-long Tang, Zan-Wen Xia, Zhao-Xu Wang. Synthesis and fungicidal Activity of Novel 
2-Aryl-3-[1, 3, 4-thiadiazolyl-6[8]-Methyl-1, 3, 4 benzoxazines. Bioorganic and Medicinal 
Chemistry.2015; 25[16]: 3378-3381. 
 
50. Bijo Mathew, A. Jerad Suresh, Githa Elizabeth Mathew, Shayam Shankar, Shayam S. 
Kumar, Synthesis Characterization and antimicrobial Screening of some[ 2-Amino 5-Phenyl 
Substituted] 1,3,4-thiadiazole derivatives. International Journal of Chem Tech Research.  
3[1]; 364-368. 
 
51. Sandeep Miglani, Monika Mishra, Pooja Chawla. The rapid Synthesis of Schiff-bases 
without Solvent under microwave irradiation and their antimicrobial activity. Der Pharma 
Chemica. 2012: 4(6):2265-2269. 
 
52. Solak N, Rollas S. Synthesis and antituberculosis activityof 2-(aryl/alkyl amino)-5-(4-
aminophenyl)-1, 3, 4-thiadiazoles and their Schiff bases. ARKIVOC: 2006; xii: 173-181. 
53. Katarzyna Brodowska, Elzbieta Lodyga- chruscinska. Schiff bases interesting range of 
applications in various fields of Science. CHEMIK. 2014:129-134. 
54. Gurdeep R. Chatwal, Sham K.Anand. Instrumental methods of chemical analysis, fifth 
edition, Himalayan Publishing houses.2005. 
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 115 
 
55. P.S Kalasi, Spectroscopy of Organic compounds, sixth edition, new age International[p] 
limited. 
56. Y.R.Sharma, Elemental Organic Spectroscopy, fifth revised edition. 2013. 
57. RobertM. Silverstein, FrancisX. Webster. Sixth edition. Wiley publishing houses, 1916; 
(212-234). 
58. LaurieAT, et.al. Q Site finder on energy based method for the prediction of protein-ligand 
binding site Bioinformatics.2004: (342-357). 
59. http; // www.modelling leads.ac.uk/q site finder/ 
60. Sanju joy, parvathy S Nair., et.al, Detailed comparison of Pro-ligdocking efficiency of 
GOLD, a commercial package and Argus lab, a licensable freeware [insilico biology 6, 
0053[2006]. 
61. http://www.organic-chemistry.org/prog/peo/retrieved on 22.12.2013.  
62. Burger’s Medicinal Chemistry, Sixth edition. Vol-8.  
63. Graham L Patrick. An introduction to Medicinal Chemistry, fourth edition, Oxford 
University Press. ISBNO-19-855872. 
64. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (March 2001). Experimental And 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv.Drug Deliv.2001;P.3-26.doi:10.1016/S0169 409X (00) 
001290.PMID 11259830. 
65. Lipinski CA (December 2004).
 
 Lead-and drug –like compounds: the rule –of-five 
revolutions. Drug Discovery Today: Technologies 2004;1(4)337-
341.doi:10.1016/j.ddtec.2004.11.007. 
66. http://e.wikipedia.org/wiki/lipinski%27s_rule_of_five.Retrived on 2.1.2014.  
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 116 
 
67. Solak N, Rollas S. Synthesis and antituberculosis activity of 2-(aryl/alkyl amino)-5-(4-
aminophenyl)-1, 3, 4-thiadiazoles and their Schiff bases. ARKIVOC: 2006; xii: 173-181. 
68. Himaja M, Karigar A, Ramana MV, Munirajasekhar D,Sikarwar MS. Synthesis of novel 
azetidinone derivatives as anti tubercular agents. Letters in Drug Design &Discovery: 2012; 
9: 611-617. 
69. Malipeddi H, Karigar A, Ramana V, Sikarwar MS. Synthesis and anti tubercular activity 
of some novel activity of nicotinic and isoniazid analogues. ARKIVOC: 2007; xv: 181-191. 
70. Shankar Gaddeppa, kallanagouda Ramappa, Europian J.of Chemistry, 2011; (21): 94-99. 
 71. Accelrys. Adme- tox Component collection Http:// accelrys.com/ pipeline. Pilot/ 
component-collections/ adme- tox.html. 
72. http://www.molinspiration.com/cgi-bin/properties.Retrieved on 7.3.2014.  
73. The Merck Index. 13
th
 edition Merck and co., Inc. White house station, N.J., U.S.A. 
Published by Merck Research laboratories, 2007. 
74. Brian Leonard, Jorge Coronel, Mark Siedner, Louis Grand jean. Inter –and Intra- Assay 
Reproducibility of Micro plate Alamar blue Assay Results for Isoniazid, Rifambicin, 
Ethambutol, Streptomycin, ciprofloxacin, and Capreomycin Drug susceptibility Testing of 
mycobacterium tuberculosis. Journal of clinical microbiology.2008; P.3526-3529. 
75. Vanitha JD, Paramasivan CN. Evaluation of Micro plate Alamar blue assay for drug 
susceptibility testing of Mycobacterium avium complex isolates. Diagnostic Microbiology 
and Infectious Disease. 2004; 49: 179-182. 
76. Franzblau SG, Witzig RS, McLaughlin JC, Torres P, Madico G, Hernandez A, Degnan M 
T, Cook MB, Quenzer VK, Ferguson RM, Gilman RH. Rapid lower technology MIC 
determination with clinical Mycobacterium tuberculosis isolates by using the Micro plate 
Alamar blue assay. Journal of Clinical Microbiology: 1998; 36: 362-366. 
                                                                        BIBILOGRAPHY 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, COP, MMC Page 117 
 
77. Todd P.Primm and Scott G. Franzblau. Recent advantages in Methodologies for the 
discovery of Anti Mycobacterial Drugs. Current Bioactive Compounds.2007; 3. 
78. Wright, e. L., D.C Querelle, W.J .Suling, and W.W. Barrow. 1996. Use of mono mac 6. 
Human monocytic cell line and j774 Murine Macrophage cell line in parallel 
antimycobacterial drug studies. Antimicrob. Agents Chem other. 40: 2206-2208. 
79. Sephra N. Ramprasad., Multiple Application Of Alamar Blue As An Indicator Of 
Metabolic Function And Cellular Health In Cell Viability Bioassays By, Sensors 
2012;(12):12347-12360.  
 80. Jose D Jesus Alba-Romero et.al, Application of the Alamar Blue Assay to Determine the 
Susceptibility to Anti-tuberculosis Pharmaceuticals. African Research Journals of 
Microbiology. 2011; 5 (26):4659-4666. 
81. Zabransky, R. J. A. R. Dinuzzo, and G. L. Woods. 1995. Detection of Vancomycin 
resistance in enterococci by the alamar mic system. J. Clin.microbiol. 33:791-793. 
 
 
 
 
 
 
